

九州がんセンター英文論文一覧 (2022)

4月～9月

#腫瘍学

ヒト上皮成長因子受容体2陽性食道胃癌および胃癌におけるERBB2コピー数および遺伝子変異とトラスツズマブの有効性および耐性との関連性についての論文

Hino K, Nishina T, Kajiwara T, Bando H, Nakamura M, Kadowaki S, Minashi K, Yuki S, Ohta T, Hara H, Mizukami T, Moriwaki T, Ohtsubo K, **Komoda M**, Mitani S, Nagashima F, Kato K, Yamada T, Hasegawa H, Yamazaki K, Yoshino T, Hyodo I

Association of ERBB2 Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2-Positive Esophagogastric and Gastric Cancer

JCO Precis Oncol. 2022;6

Journal Impact Factor 2021: 5.479

PMID: 35952320 (<https://pubmed.ncbi.nlm.nih.gov/35952320>) DOI: 10.1200/PO.22.00135

(<https://doi.org/10.1200/PO.22.00135>) WoS: WOS:000975488400060

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000975488400060>)

#放射線学 #核医学 #医用画像

乳腺のダイナミック磁気共鳴画像による浸潤性乳癌と非浸潤性乳癌の定量的分類についての論文

Miyazaki Y, Shimizu J, **Kubo Y**, **Tabata N**, Aso T

Quantitative classification of invasive and noninvasive breast cancer using dynamic magnetic resonance imaging of the mammary gland

J Clin Imag Sci. 2022 AUG 5;12

Journal Impact Factor 2021: N/A

PMID: 36128357 (<https://pubmed.ncbi.nlm.nih.gov/36128357>) DOI: 10.25259/JCIS_56_2022

(https://doi.org/10.25259/JCIS_56_2022) WoS: WOS:000933487900001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000933487900001>)

#腫瘍学 #第II相試験 #ランダム化比較試験

EGFR遺伝子変異を有する未治療の非扁平上皮NSCLC患者に対するオシメルチニブとベバシズマブの併用療法とオシメルチニブの無作為化第2相試験WJOG9717L試験についての論文

Kenmotsu H, Wakuda K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K, Teraoka S, Shukuya T, Masuda K, Hayashi H, **Toyozawa R**, Miura S, Fujimoto D, Nakagawa K, Yamamoto N, Takahashi T

Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study

J Thorac Oncol. 2022 SEP;17(9):1098-1108.

Journal Impact Factor 2021: 20.121

PMID: 35636696 (<https://pubmed.ncbi.nlm.nih.gov/35636696>) DOI: 10.1016/j.jtho.2022.05.006

(<https://doi.org/10.1016/j.jtho.2022.05.006>) WoS: WOS:000898620700016

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000898620700016>)

#腫瘍学

卵巣明細胞癌および子宮内膜癌におけるミスマッチ修復機能欠損の頻度と臨床的特徴についての論文

Tanaka T, Takehara K, Yamashita N, Okazawa-Sakai M, Kuraoka K, Teramoto N, **Taguchi K**, Yamashiro K, Kato H, Mizunoe T, Suzuki R, Yamamoto D, Ueki A, **Saito T**

Frequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinoma

J Gynecol Oncol. 2022 SEP;33(5)

Journal Impact Factor 2021: 4.756

PMID: 36032025 (<https://pubmed.ncbi.nlm.nih.gov/36032025>) DOI: 10.3802/jgo.2022.33.e67
(<https://doi.org/10.3802/jgo.2022.33.e67>) WoS: WOS:000864125100008
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000864125100008>)

#皮膚病学 #多施設共同研究

進行性メラノーマに対する抗PD-1抗体のアジュバント療法：日本人78例の多施設共同研究についての論文

Muto Y, Kambayashi Y, Kato H, Fukushima S, Ito T, Maekawa T, Fujisawa Y, Yoshino K, Uchi H, Matsushita S, Yamamoto Y, Amagai R, Ohuchi K, Hashimoto A, Fujimura T

Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases

Acta Derm-Venereol. 2022 AUG;102

Journal Impact Factor 2021: 3.875

PMID: 35670329 (<https://pubmed.ncbi.nlm.nih.gov/35670329>) DOI: 10.2340/actadv.v102.678
(<https://doi.org/10.2340/actadv.v102.678>) WoS: WOS:000860611800002
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000860611800002>)

#複合科学

EWS-FLI1 融合遺伝子を持つユーイング肉腫細胞における染色体転座による組換え修復の活性化についての論文

Tanaka K, Suzuki K, Miyashita K, Wakasa K, Kawano M, Nakatsu Y, Tsumura H, Yoshida MA, Oda S

Activation of recombinational repair in Ewing sarcoma cells carrying EWS-FLI1 fusion gene by chromosome translocation

Sci Rep. 2022 AUG 30;12(1)

Journal Impact Factor 2021: 4.997

PMID: 36042341 (<https://pubmed.ncbi.nlm.nih.gov/36042341>) DOI: 10.1038/s41598-022-19164-x
(<https://doi.org/10.1038/s41598-022-19164-x>) WoS: WOS:000847803100034
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000847803100034>)

#外科学

思春期に発生した肝臓の未分化胚性肉腫：ゲノム解析を伴う症例報告についての論文

Shimagaki T, Sugimachi K, Mano Y, Onishi E, Tanaka Y, Sugimoto R, Taguchi K, Morita M, Toh Y

Undifferentiated embryonal sarcoma of the liver occurring in an adolescent: a case report with genomic analysis

SURG CASE REP. 2022 SEP 15;8(1)

Journal Impact Factor 2021: N/A

PMID: 36107353 (<https://pubmed.ncbi.nlm.nih.gov/36107353>) DOI: 10.1186/s40792-022-01528-0
(<https://doi.org/10.1186/s40792-022-01528-0>) WoS: WOS:000854761400001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000854761400001>)

#腫瘍学

カルボプラチンをベースとした化学療法を受けているNSCLC患者における化学療法誘発性の悪心・嘔吐に対する制吐剤の併用療法についての論文

Shimokawa M, Haratake N, Takada K, Toyokawa G, Takamori S, Mizuki F, Takenaka T, Hayashi T

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy

Cancer Manag Res. 2022;14:2673-2680.

Journal Impact Factor 2021: 3.602

PMID: 36110158 (<https://pubmed.ncbi.nlm.nih.gov/36110158>) DOI: 10.2147/CMAR.S370961
(<https://doi.org/10.2147/CMAR.S370961>) WoS: WOS:000853817900001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000853817900001>)

#腫瘍学

低分子MET阻害剤で治療中のMETエクソン14変異非小細胞肺癌患者における末梢性浮腫の管理についての論文

Nishio M, Kato T, Toyozawa R, Hida T

Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors

Target Oncol. 2022 SEP;17(5):597-604.

Journal Impact Factor 2021: 4.897

PMID: 36087188 (<https://pubmed.ncbi.nlm.nih.gov/36087188>) DOI: 10.1007/s11523-022-00912-y

(<https://doi.org/10.1007/s11523-022-00912-y>) WoS: WOS:000852369400001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000852369400001>)

#医学 #一般医療 #内科学

進行性膵臓癌患者におけるゲムシタビンベース療法後のフルオロウラシルおよびフォリン酸を併用したNanoliposomal Irinotecanの治療効果および安全性。多施設共同前向き観察研究についての論文

Miki M, Fujimori N, Ueda K, Lee L, Murakami M, Takamatsu Y, Shimokawa Y, Niina Y, Oono T, Hisano T, Furukawa M, Ogawa Y

Treatment Effect and Safety of Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid after Gemcitabine-Based Therapy in Patients with Advanced Pancreatic Cancer: A Multicenter, Prospective Observational Study

J Clin Med. 2022 SEP;11(17)

Journal Impact Factor 2021: 4.964

PMID: 36079012 (<https://pubmed.ncbi.nlm.nih.gov/36079012>) DOI: 10.3390/jcm11175084

(<https://doi.org/10.3390/jcm11175084>) WoS: WOS:000851139200001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000851139200001>)

#腫瘍学

未熟なテラトーマの神経外胚葉性ロゼットは、多層ロゼットを持つ胚性腫瘍の対極にあるわけではないについての論文

Magarifuchi N, Yamada Y, Oishi Y, Kato K, Taguchi K, Oda Y

Neuroectodermal Rosettes in Immature Teratomas Are Not the Counterpart of Embryonal Tumours With Multilayered Rosettes

Anticancer Res. 2022 SEP;42(9):4337-4344.

Journal Impact Factor 2021: 2.435

PMID: 36039462 (<https://pubmed.ncbi.nlm.nih.gov/36039462>) DOI: 10.21873/anticancerres.15934

(<https://doi.org/10.21873/anticancerres.15934>) WoS: WOS:000848355500016

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000848355500016>)

#免疫学 #多施設共同研究

直接作用型抗ウイルス薬で治療中の75-84歳のC型慢性肝炎患者における肝細胞癌の発生についての論文

Ogawa E, Nomura H, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Ichiki Y, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Hayashi J, Kyushu Univ Liver Dis Study KULDS

Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals

J Infect Dis. 2022 AUG 26;226(3):431-440.

Journal Impact Factor 2021: 7.759

PMID: 32584386 (<https://pubmed.ncbi.nlm.nih.gov/32584386>) DOI: 10.1093/infdis/jiaa359

(<https://doi.org/10.1093/infdis/jiaa359>) WoS: WOS:000845748200008

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000845748200008>)

#医学 #研究 #実験 #メタアナリシス #レビュー論文 #システマティックレビュー

一次治療として化学免疫療法併用療法を受けた非小細胞肺癌患者における性別と転帰の関連性：無作為化臨床試験の系統的レビューとメタ分析についての論文

Takada K, Shimokawa M, Mizuki F, Takamori S, Takenaka T, Miura N, Shikada Y, Yoshizumi T

Association between sex and outcomes in patients with non-small-cell lung cancer receiving combination chemoimmunotherapy as a first-line therapy: a systematic review and meta-analysis of randomized clinical trials

Eur J Med Res. 2022 AUG 23;27(1)

Journal Impact Factor 2021: 4.981

PMID: 35999618 (<https://pubmed.ncbi.nlm.nih.gov/35999618>) DOI: 10.1186/s40001-022-00789-7

(<https://doi.org/10.1186/s40001-022-00789-7>) WoS: WOS:000843703500003

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000843703500003>)

#生化学 #分子生物学 #第III相試験 #ランダム化比較試験

血中腫瘍変異負荷が高い進行性・転移性NSCLCにおけるアテゾリズマブと化学療法の比較：BFASTコホートC無作為化第3相試験の主要解析結果についての論文

Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchavijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocchi S, Voong D, Fabrizio DA, Shames DS, Riehl T, Gandara DR, Mok T

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Nat Med. 2022 SEP;28(9):1831-1839.

Journal Impact Factor 2021: 87.244

PMID: 35995953 (<https://pubmed.ncbi.nlm.nih.gov/35995953>) DOI: 10.1038/s41591-022-01933-w

(<https://doi.org/10.1038/s41591-022-01933-w>) WoS: WOS:000842907100002

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000842907100002>)

#腫瘍学

PD-1チェックポイント阻害薬による治療を受けた非小細胞肺癌患者におけるプロバイオティクスの抗生物質依存的な効果についての論文

Takada K, Buti S, Bersanelli M, Shimokawa M, Takamori S, Matsubara T, Takenaka T, Okamoto T, Hamatake M, Tsuchiya-Kawano Y, Otsubo K, Nakanishi Y, Okamoto I, Pinato DJ, Cortellini A, Yoshizumi T

Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade

Eur J Cancer. 2022 SEP;172:199-208.

Journal Impact Factor 2021: 10.002

PMID: 35780526 (<https://pubmed.ncbi.nlm.nih.gov/35780526>) DOI: 10.1016/j.ejca.2022.06.002

(<https://doi.org/10.1016/j.ejca.2022.06.002>) WoS: WOS:000833528400017

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000833528400017>)

#腫瘍学

前治療の免疫チェックポイント阻害剤が奏効し、ICI-Freeインターバルを有する非小細胞肺癌患者におけるNivolumabの再治療 (WJOG9616L)についての論文

Akamatsu H, Teraoka S, Takamori S, Miura S, Hayashi H, Hata A, Toi Y, Shiraishi Y, Mamesaya N, Sato Y, Furuya N, Oyanagi J, Koh Y, Misumi T, Yamamoto N, Nakagawa K

Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)

Clin Cancer Res. 2022 AUG 1;28(15):3207-3213.

Journal Impact Factor 2021: 13.801

DOI: 10.1158/1078-0432.CCR-22-0602 (<https://doi.org/10.1158/1078-0432.CCR-22-0602>) WoS:

WOS:000835653500001 (<https://www.webofscience.com/wos/woscc/full-record/WOS:000835653500001>)

#ヘルスケア科学 #サービス

終末期における低活動性せん妄に対する医師の信念と態度についての論文

Oya K, Morita T, Tagami K, Matsuda Y, Naito AS, Kashiwagi H, Otani H

Physicians' Beliefs and Attitudes Toward Hypoactive Delirium in The Last Days of Life

J Pain Symptom Manage. 2022 AUG;64(2):110-118.

Journal Impact Factor 2021: 5.576

PMID: 35490994 (<https://pubmed.ncbi.nlm.nih.gov/35490994>) DOI: 10.1016/j.jpainsymman.2022.04.176

(<https://doi.org/10.1016/j.jpainsymman.2022.04.176>) WoS: WOS:001072967800011

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001072967800011>)

#腫瘍学 #第II相試験

治療歴のないEGFR変異型非小細胞肺癌に対するナザルチニブ。第2相、単群、非盲検試験の結果についての論文

Tan DSW, Kim SW, Aix SP, Sequist LV, Smit EF, Yang JCH, Hida T, Toyozawa R, Felip E, Wolf J, Grohé C, Leighl NB, Riely G, Cui XM, Zou MK, Ghebremariam S, O'Sullivan-Djentuh L, Belli R, Giovannini M, Kim DW

Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study

Eur J Cancer. 2022 SEP;172:276-286.

Journal Impact Factor 2021: 10.002

PMID: 35810553 (<https://pubmed.ncbi.nlm.nih.gov/35810553>) DOI: 10.1016/j.ejca.2022.05.023

(<https://doi.org/10.1016/j.ejca.2022.05.023>) WoS: WOS:000829363200003

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000829363200003>)

#腫瘍学 #第II相試験

局所進行胸腺癌に対するS-1 + シスプラチンと同時放射線治療の第II相試験。LOGIK1605/JART-1501 試験の結果についての論文

Fukuda M, **Yamaguchi M**, Yamazaki T, Funaki S, Mukae H, Fukuoka J, Nabeshima K, Tateyama H, Ashizawa K, Tomiyama N, Hara M, **Seto T**, Okumura M, Sugio K

Phase II study of S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Results of the LOGIK1605/JART-1501 study

Thorac Cancer. 2022 SEP;13(17):2499-2506.

Journal Impact Factor 2021: 3.223

PMID: 35869676 (<https://pubmed.ncbi.nlm.nih.gov/35869676>) DOI: 10.1111/1759-7714.14586

(<https://doi.org/10.1111/1759-7714.14586>) WoS: WOS:000828904000001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000828904000001>)

#複合科学 #多施設共同研究

再発・転移性頭頸部扁平上皮がんに対する免疫チェックポイント阻害薬投与後のサルベージ化学療法としての週1回パクリタキセルとセツキシマブの有効性と安全性：多施設共同臨床試験についての論文

Wakasaki T, Manako T, Yasumatsu R, **Hara H**, **Toh S**, **Masuda M**, Yamauchi M, Kuratomi Y, Nishimura E, Takeuchi T, Matsuo M, Jiromaru R, Hashimoto K, Komune N, Nakagawa T

Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study

PLoS One. 2022 JUL 28;17(7)

Journal Impact Factor 2021: 3.752

PMID: 35901098 (<https://pubmed.ncbi.nlm.nih.gov/35901098>) DOI: 10.1371/journal.pone.0271907

(<https://doi.org/10.1371/journal.pone.0271907>) WoS: WOS:001046272400003

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001046272400003>)

#腫瘍学 #多施設共同研究 #観察研究

一次治療として分子標的薬を投与されたRAS野生型大腸がん患者の生存率予測因子としての原発巣位置：日本結腸直腸癌学会による多施設実地観察研究についての論文

Ito T, Takashima A, Yamazaki K, Yukami H, Uetake H, Tsuda M, Suto T, Moriwaki T, Sugimoto N, Ojima H, Takii Y, Yasui H, **Esaki T**, Tsuji A, Goto M, Saruta M, Otsu S, Shinozaki K, Fujiwara T, Tamura T, Baba E, Shiozawa M, Denda T, Ueno H, Nagashima K, Shimada Y

Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum

Int J Clin Oncol. 2022 SEP;27(9):1450-1458.

Journal Impact Factor 2021: 3.85

PMID: 35861943 (<https://pubmed.ncbi.nlm.nih.gov/35861943>) DOI: 10.1007/s10147-022-02208-7

(<https://doi.org/10.1007/s10147-022-02208-7>) WoS: WOS:000828454300001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000828454300001>)

#血液学

TKI時代におけるCML患者（小児および青年/若年成人）に対する同種造血幹細胞移植の予後予測因子についての論文

Shimada H, Tanizawa A, Kondo T, Nagamura-Inoue T, Yasui M, Tojo A, Muramatsu H, Eto T, Doki N, Tanaka M, Sato M, **Noguchi M**, Uchida N, Takahashi Y, Sakata N, Ichinohe T, Hashii Y, Kato K, Atsuta Y, Ohashi K, Japanese Soc Transplantation Cellu

Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents/Young Adults With CML in the TKI Era

Transpl Cell Ther. 2022 JUL;28(7):376-389.

Journal Impact Factor 2021: N/A

PMID: 35447373 (<https://pubmed.ncbi.nlm.nih.gov/35447373>) DOI: 10.1016/j.jtct.2022.04.011

(<https://doi.org/10.1016/j.jtct.2022.04.011>) WoS: WOS:000827884400016

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000827884400016>)

#腫瘍学 #第I相試験 #第II相試験

日本における未治療の低悪性度B細胞性非ホジキンリンパ腫、マントル細胞リンパ腫、再発・難治性のびまん性大細胞型B細胞リンパ腫を対象としたベンダムスチン塩酸塩（速注製剤）の10分間投与に関する第I/II相試験についての論文

Ishizawa K, Yokoyama M, Kato H, Yamamoto K, Makita M, Ando K, Ueda Y, **Tachikawa Y**, **Suehiro Y**, Kurosawa M, Kameoka Y, Nagai H, Uoshima N, Ishikawa T, Hidaka M, Ito Y, Utsunomiya A, Fukushima K, Ogura M

A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan

Cancer Chemother Pharmacol. 2022 JUL;90(1):83-95.

Journal Impact Factor 2021: 3.288

PMID: 35796785 (<https://pubmed.ncbi.nlm.nih.gov/35796785>) DOI: 10.1007/s00280-022-04442-2

(<https://doi.org/10.1007/s00280-022-04442-2>) WoS: WOS:000825393700002

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000825393700002>)

#細胞生物学

膵臓ハマルトーマ：NAB2::STAT6融合遺伝子を保有することの検出についての論文

Tanigawa M, Koga Y, **Naito Y**, Yamaguchi H, Iwasaki T, Kohashi K, Ohike N, Hanada K, Higashi M, Komatsu M, Imai H, Yamakita K, Nagakawa T, Okabe Y, Kato S, Noguchi H, Nakayama T, Yasuda M, **Kusano H**, Akiba J, Oda Y, **Yano H**

Pancreatic hamartoma: detection of harbouring NAB2::STAT6 fusion gene

Histopathology. 2022 SEP;81(3):319-328.

Journal Impact Factor 2021: 7.778

PMID: 35758200 (<https://pubmed.ncbi.nlm.nih.gov/35758200>) DOI: 10.1111/his.14703

(<https://doi.org/10.1111/his.14703>) WoS: WOS:000825270600001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000825270600001>)

#腫瘍学

早期子宮頸癌に対するセンチネルリンパ節生検単独術後の長期フォローアップについての論文

Yahata H, Kodama K, Okugawa K, Hachisuga K, Yasutake N, Maenohara S, Yagi H, Yasunaga M, Ohgami T, Onoyama I, Asanoma K, Kobayashi H, **Sonoda K**, Baba S, Ishigami K, Ohishi Y, Oda Y, Kato K

Long-term follow up after sentinel node biopsy alone for early-stage cervical cancer

Gynecol Oncol. 2022 APR;165(1):149-154.

Journal Impact Factor 2021: 5.304

PMID: 35151491 (<https://pubmed.ncbi.nlm.nih.gov/35151491>) DOI: 10.1016/j.ygyno.2022.01.031

(<https://doi.org/10.1016/j.ygyno.2022.01.031>) WoS: WOS:000820704700022

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000820704700022>)

#腫瘍学

小型肺腺癌における圧密腫瘍比率と腫瘍浸潤リンパ球の関係についての論文

Ono Y, Tagawa T, **Kinoshita F**, Haratake N, Takada K, Kohno M, Takenaka T, Kamitani T, Shimokawa M, Oda Y, Mori M, Yoshizumi T

Relationship between consolidation tumor ratio and tumor-infiltrating lymphocytes in small-sized lung adenocarcinoma

Thorac Cancer. 2022 AUG;13(15):2134-2141.

Journal Impact Factor 2021: 3.223

PMID: 35791738 (<https://pubmed.ncbi.nlm.nih.gov/35791738>) DOI: 10.1111/1759-7714.14524
(<https://doi.org/10.1111/1759-7714.14524>) WoS: WOS:000820963500001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000820963500001>)

#腫瘍学 #第II相試験

胃がんに対する初回化学療法として、PembrolizumabとS-1+oxaliplatinまたはS-1+cisplatinを併用する第IIb相試験についての論文

Yamaguchi K, Minashi K, Sakai D, Nishina T, Omuro Y, Tsuda M, Iwagami S, Kawakami H, **Esaki T**, Sugimoto N, Oshima T, Kato K, Amagai K, Hosaka H, Komine K, Yasui H, Negoro Y, Ishido K, Tsushima T, Han SR, Shiratori S, Takami T, Shitara K

Phase IIb study of pembrolizumab combined with S-1+oxaliplatin or S-1+cisplatin as first-line chemotherapy for gastric cancer

Cancer Sci. 2022 AUG;113(8):2814-2827.

Journal Impact Factor 2021: 6.518

PMID: 35701865 (<https://pubmed.ncbi.nlm.nih.gov/35701865>) DOI: 10.1111/cas.15462
(<https://doi.org/10.1111/cas.15462>) WoS: WOS:000819603500001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000819603500001>)

#医学 #研究 #実験 #観察研究

ニボルマブで治療した頭頸部がん患者の5年追跡調査と2年以上の長期奏効者についての論文

Matsuo M, Yasumatsu R, **Masuda M**, Yamauchi M, Wakasaki T, Hashimoto K, Jiramaru R, Manako T, Nakagawa T

Five-year Follow-up of Patients With Head and Neck Cancer Treated With Nivolumab and Long-term Responders for Over Two Years

In Vivo. 2022 JUL-AUG;36(4):1881-1886.

Journal Impact Factor 2021: 2.406

PMID: 35738615 (<https://pubmed.ncbi.nlm.nih.gov/35738615>) DOI: 10.21873/invivo.12907
(<https://doi.org/10.21873/invivo.12907>) WoS: WOS:000818929900025
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000818929900025>)

#腫瘍学 #第II相試験 #ランダム化比較試験

進行した非扁平上皮成長因子受容体陽性の非小細胞肺癌患者に対する一次治療としてのエルロチニブとベバシズマブの併用または非併用。第II相試験（JO25567試験）の探索的サブグループ解析結果についての論文

Hosomi Y, **Seto T**, Nishio M, Goto K, Yamamoto N, Okamoto I, Tajima K, Kajihara Y, Yamamoto N

Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study

Thorac Cancer. 2022 AUG;13(15):2192-2200.

Journal Impact Factor 2021: 3.223

PMID: 35768976 (<https://pubmed.ncbi.nlm.nih.gov/35768976>) DOI: 10.1111/1759-7714.14541
(<https://doi.org/10.1111/1759-7714.14541>) WoS: WOS:000818599900001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000818599900001>)

#環境科学

メッシュ型基準計算ファントムを用いた画像誘導放射線治療におけるコーンビームCTの線量推定と頭頸部癌を想定した場合についての論文

Cumur C, Fujibuchi T, **Hamada K**

Dose estimation for cone-beam computed tomography in image-guided radiation therapy using mesh-type reference computational phantoms and assuming head and neck cancer

J Radiol Prot. 2022 JUN 1;42(2)

Journal Impact Factor 2021: 1.559

PMID: 35705020 (<https://pubmed.ncbi.nlm.nih.gov/35705020>) DOI: 10.1088/1361-6498/ac7914
(<https://doi.org/10.1088/1361-6498/ac7914>) WoS: WOS:000818636300001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000818636300001>)

#腫瘍学 #第II相試験

ALK陽性の進行非小細胞肺癌患者（アジア人および非アジア人）におけるロルラチニブの有効性と安全性。国際共同第2相試験のサブグループ解析についての論文

Soo RA, Tan EH, Hayashi H, **Seto T**, Lin CC, Ou SHI, Kim DW, Liu GF, Abbattista A, Martini JF, Martini F, Wong CH, Toffalorio F, Solomon BJ

Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial

Lung Cancer. 2022 JUL;169:67-76.

Journal Impact Factor 2021: 6.081

PMID: 35660971 (<https://pubmed.ncbi.nlm.nih.gov/35660971>) DOI: 10.1016/j.lungcan.2022.05.012

(<https://doi.org/10.1016/j.lungcan.2022.05.012>) WoS: WOS:000814794800003

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000814794800003>)

#腫瘍学 #第III相試験 #ランダム化比較試験

大腸癌における逐次治療と併用治療の第3相試験：C-cubed試験についての論文

Inada R, Nagasaka T, **Shimokawa M**, Ojima H, Noura S, Tanioka H, Munemoto Y, Shimada Y, Ishibashi K, Shindo Y, Mishima H, Okajima M, Yamaguchi Y

Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study

Eur J Cancer. 2022 JUL;169:166-178.

Journal Impact Factor 2021: 10.002

PMID: 35569283 (<https://pubmed.ncbi.nlm.nih.gov/35569283>) DOI: 10.1016/j.ejca.2022.04.009

(<https://doi.org/10.1016/j.ejca.2022.04.009>) WoS: WOS:001040904500001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001040904500001>)

#消化器病学 #肝臓学 #多施設共同研究

ヌクレオシド (t) イドアナログ経験者のB型慢性肝炎患者に対するテノホビルアラフェナミドへの切替。多施設共同コホート研究による144週目の結果についての論文

Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, **Sugimoto R**, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J, Kyushu Univ Liver Dis Study KULDS

Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: Week 144 results from a real-world, multicentre cohort study

Aliment Pharmacol Ther. 2022 AUG;56(4):713-722.

Journal Impact Factor 2021: 9.524

PMID: 35735794 (<https://pubmed.ncbi.nlm.nih.gov/35735794>) DOI: 10.1111/apt.17107

(<https://doi.org/10.1111/apt.17107>) WoS: WOS:000814678000001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000814678000001>)

#腫瘍学 #第III相試験 #ランダム化比較試験

EGFR遺伝子変異陽性の進行性非小細胞肺癌に対するペメトレキセドの使用による生存率の向上（ゲフィチニブとシスプラチン+ドセタキセルの無作為化第III相比較試験）（WJTOG3405）についての論文

Haratake N, Shimokawa M, **Seto T**, Yoshioka H, Yamamoto N, Nakagawa K, Mitsudomi T

Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405)

Int J Clin Oncol. 2022 SEP;27(9):1404-1412.

Journal Impact Factor 2021: 3.85

PMID: 35723758 (<https://pubmed.ncbi.nlm.nih.gov/35723758>) DOI: 10.1007/s10147-022-02193-x

(<https://doi.org/10.1007/s10147-022-02193-x>) WoS: WOS:000813629900001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000813629900001>)

#腫瘍学

大腸がんにおけるBRAF(V600E)変異およびマイクロサテライト不安定性の検出を目的とした病理学的解釈を用いた迅速なスクリーニング法についての論文

Fujii S, Kotani D, Hattori M, Nishihara M, Shikanai T, Hashimoto J, Hama Y, Nishino T, Suzuki M, Yoshidumi A, Ueno M, Komatsu Y, Masuishi T, Hara H, **Esaki T**, Nakamura Y, Bando H, Yamada T, Yoshino T

Rapid Screening Using Pathomorphologic Interpretation to Detect BRAF^{V600E} Mutation and Microsatellite Instability in Colorectal Cancer

Clin Cancer Res. 2022 JUN 15;28(12):2623-2632.

Journal Impact Factor 2021: 13.801

PMID: 35363302 (<https://pubmed.ncbi.nlm.nih.gov/35363302>) DOI: 10.1158/1078-0432.CCR-21-4391

(<https://doi.org/10.1158/1078-0432.CCR-21-4391>) WoS: WOS:000813192700001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000813192700001>)

#腫瘍学

定位切除放射線治療前のステージ非小細胞肺癌患者の治療計画CT画像におけるトポロジースグネチャーの再発予測可能性についての論文

Kodama T, Arimura H, **Shirakawa Y**, Ninomiya K, Yoshitake T, Shioyama Y

Relapse predictability of topological signature on pretreatment planning CT images of stage I non-small cell lung cancer patients before treatment with stereotactic ablative radiotherapy

Thorac Cancer. 2022 AUG;13(15):2117-2126.

Journal Impact Factor 2021: 3.223

PMID: 35711108 (<https://pubmed.ncbi.nlm.nih.gov/35711108>) DOI: 10.1111/1759-7714.14483

(<https://doi.org/10.1111/1759-7714.14483>) WoS: WOS:000811891700001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000811891700001>)

#医学 #一般医療 #内科学

肺癌における免疫療法の治療効果予測バイオマーカーとしての人工知能由来腸内細菌叢：多施設共同前向き観察研究プロトコールについての論文

Shoji F, Yamashita T, Kinoshita F, Takamori S, Fujishita T, Toyozawa R, Ito K, Yamazaki K, Nakashima N, **Okamoto T**

Artificial intelligence-derived gut microbiome as a predictive biomarker for therapeutic response to immunotherapy in lung cancer: protocol for a multicentre, prospective, observational study

BMJ Open. 2022 JUN;12(6)

Journal Impact Factor 2021: 3.007

PMID: 35676015 (<https://pubmed.ncbi.nlm.nih.gov/35676015>) DOI: 10.1136/bmjopen-2022-061674

(<https://doi.org/10.1136/bmjopen-2022-061674>) WoS: WOS:000810036900022

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000810036900022>)

#複合科学 #多施設共同研究

免疫チェックポイント阻害剤投与患者における術後再発非小細胞肺癌の予後に及ぼす併用薬使用の臨床的影響についての論文

Takada K, **Shimokawa M**, Takamori S, Shimamatsu S, Hirai F, Ono Y, Tagawa T, **Okamoto T**, Hamatake M, Okamoto I, Mori M

The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors

PLoS One. 2022 FEB 7;17(2)

Journal Impact Factor 2021: 3.752

PMID: 35130287 (<https://pubmed.ncbi.nlm.nih.gov/35130287>) DOI: 10.1371/journal.pone.026324

(<https://doi.org/10.1371/journal.pone.026324>) WoS: WOS:000805530700022

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000805530700022>)

#腫瘍学 #多施設共同研究

経口ヒストン脱アセチル化酵素阻害剤tucidinostat (HBI-8000) の再発又は難治性の成人T細胞白血病/リンパ腫患者に対する試験。第IIb相試験結果についての論文

Utsunomiya A, Izutsu K, Jo T, Yoshida S, Tsukasaki K, Ando K, **Choi I**, Imaizumi Y, Kato K, Kurosawa M, Kusumoto S, Miyagi T, Ohtsuka E, Sasaki O, Shibayama H, Shimoda K, Takamatsu Y, Takano K, Yonekura K, Makita S, Taguchi J, Gillings M, Onogi H, Tobinai K

Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: Phase IIb results

Cancer Sci. 2022 AUG;113(8):2778-2787.

Journal Impact Factor 2021: 6.518

PMID: 35579212 (<https://pubmed.ncbi.nlm.nih.gov/35579212>) DOI: 10.1111/cas.15431

(<https://doi.org/10.1111/cas.15431>) WoS: WOS:000807532400001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000807532400001>)

#医学 #一般医療 #内科学 #第III相試験 #ランダム化比較試験

前治療歴のあるHER2低下進行乳癌に対するTrastuzumab Deruxtecanの投与についての論文

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, **Tokunaga E**, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu BH, Wang XJ, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung LT, Wang YB, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

N Engl J Med. 2022 JUL 7;387(1):9-20.

Journal Impact Factor 2021: 176.082

PMID: 35665782 (<https://pubmed.ncbi.nlm.nih.gov/35665782>) DOI: 10.1056/NEJMoa2203690

(<https://doi.org/10.1056/NEJMoa2203690>) WoS: WOS:000806835900001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000806835900001>)

#病理学 #多施設共同研究

子宮内膜間質性肉腫の病理診断の不一致：日本臨床腫瘍学会による多施設共同レトロスペクティブスタディについての論文

Yoshida H, Kikuchi A, Tsuda H, Sakamoto A, Fukunaga M, Kaku T, Yoshida M, Shikama A, Kogata Y, Terao Y, Tanikawa M, Yasuoka T, Chiyoda T, Miyamoto T, **Okadome M**, Nakamura T, Enomoto T, Konno Y, Yahata H, Hirata Y, Aoki Y, Tokunaga H, Usui H, Yaegashi N

Discrepancies in pathological diagnosis of endometrial stromal sarcoma: a multi-institutional retrospective study from the Japanese clinical oncology group

Hum Pathol. 2022 JUN;124:24-35.

Journal Impact Factor 2021: 3.526

PMID: 35339567 (<https://pubmed.ncbi.nlm.nih.gov/35339567>) DOI: 10.1016/j.humpath.2022.03.007

(<https://doi.org/10.1016/j.humpath.2022.03.007>) WoS: WOS:000803852800003

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000803852800003>)

#病理学 #レビュー論文

集合管癌の再分類とSMARCB1/INI1欠損腎細胞癌およびフマル酸ヒドラターゼ欠損腎細胞癌との比較病理学的解析の試みについての論文

Kiyozawa D, Kohashi K, Takamatsu D, Iwasaki T, Shibata D, Tomonaga T, Tateishi Y, Eto M, Kinjo M, Nishiyama K, **Taguchi K**, Oshiro Y, Kuboyama Y, Furuya M, Oda Y

Approach for reclassification of collecting duct carcinoma and comparative histopathological analysis with SMARCB1/INI1-deficient renal cell carcinoma and fumarate hydratase-deficient renal cell carcinoma

Hum Pathol. 2022 JUN;124:36-44.

Journal Impact Factor 2021: 3.526

PMID: 35306021 (<https://pubmed.ncbi.nlm.nih.gov/35306021>) DOI: 10.1016/j.humpath.2022.03.002

(<https://doi.org/10.1016/j.humpath.2022.03.002>) WoS: WOS:000803852800004

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000803852800004>)

#腫瘍学 #多施設共同研究

経口ヒストン脱アセチル化酵素阻害剤HBI-8000 (tucidinostat) の日本人再発・難治性非ホジキンリンパ腫患者における安全性と有効性：第I相試験についての論文

Yoshimitsu M, Ando K, Ishida T, Yoshida S, **Choi I**, Hidaka M, Takamatsu Y, Gillings M, Lee GT, Onogi H, Tobinai K

Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin's lymphoma: phase I safety and efficacy

Jpn J Clin Oncol. 2022 SEP 18;52(9):1014-1020.

Journal Impact Factor 2021: 2.925

PMID: 35649345 (<https://pubmed.ncbi.nlm.nih.gov/35649345>) DOI: 10.1093/jjco/hyac086
(<https://doi.org/10.1093/jjco/hyac086>) WoS: WOS:000804255100001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000804255100001>)

#腫瘍学

転移性大腸がん患者における転移部位が血中腫瘍DNAに及ぼす影響についての論文

Bando H, Nakamura Y, Taniguchi H, Shiozawa M, Yasui H, **Esaki T**, Kagawa Y, Denda T, Satoh T, Yamazaki K, Sunakawa Y, Kato T, Goto M, Yuki S, Nishina T, Oki E, Shinozaki E, Matsuhashi N, Takahashi N, Tsuji A, Ohtsubo K, Wakabayashi M, Ikeno T, Hata M, Odegaard JI, Yoshino T

Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer
JCO Precis Oncol. 2022 MAY;6

Journal Impact Factor 2021: 5.479

PMID: 35544728 (<https://pubmed.ncbi.nlm.nih.gov/35544728>) DOI: 10.1200/PO.21.00535
(<https://doi.org/10.1200/PO.21.00535>) WoS: WOS:000799932300001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000799932300001>)

#腫瘍学

ペムブロリズマブによる治療を受けた進行性尿路上皮がん患者における免疫関連有害事象と有効性、相対的好酸球数の変化との関連性についての論文

Furubayashi N, Minato A, **Negishi T**, Sakamoto N, Song Y, Hori Y, Tomoda T, Harada M, Tamura S, **Miura A**, **Komori H**, Kuroiwa K, Seki N, Fujimoto N, **Nakamura M**

Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab
Cancer Manag Res. 2022;14:1641-1651.

Journal Impact Factor 2021: 3.602

PMID: 35535266 (<https://pubmed.ncbi.nlm.nih.gov/35535266>) DOI: 10.2147/CMAR.S360473
(<https://doi.org/10.2147/CMAR.S360473>) WoS: WOS:000797538500009
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000797538500009>)

#腫瘍学 #多施設共同研究

脱分化型およびグレード3軟骨肉腫の臨床的特徴および治療成績。多施設共同研究についての論文

Kozawa E, Nishida Y, Kawai A, Hayakawa K, **Setzu N**, Kawashima H, Iwata S, Tsuchiya H, Tsukushi S, Takenaka S, Imanishi J, Baba I, Nagano A, Morii T, Shirai T, Shimizu K, Kawano H

Clinical features and treatment outcomes of dedifferentiated and grade 3 chondrosarcoma: A multi-institutional study

Cancer Sci. 2022 JUL;113(7):2397-2408.

Journal Impact Factor 2021: 6.518

PMID: 35485870 (<https://pubmed.ncbi.nlm.nih.gov/35485870>) DOI: 10.1111/cas.15382
(<https://doi.org/10.1111/cas.15382>) WoS: WOS:000797222400001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000797222400001>)

#医学 #一般医療 #内科学 #症例報告

多発性リンパ節腫脹を呈した乳癌患者において超音波ガイド下経気管支針吸引法がサルコイドーシスの診断を容易にした一例：症例報告についての論文

Oride Y, **Koi Y**, Sasada T, Kajitani K, Ohara M, Kondo T, Daimaru Y, Kawamura S

Endobronchial ultrasound-guided transbronchial needle aspiration facilitating diagnosis of sarcoidosis in a breast cancer patient with multiple lymphadenopathy: a case report

J Med Case Rep. 2022 MAY 19;16(1)

PMID: 35585552 (<https://pubmed.ncbi.nlm.nih.gov/35585552>) DOI: 10.1186/s13256-022-03428-1
(<https://doi.org/10.1186/s13256-022-03428-1>) WoS: WOS:000797510900001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000797510900001>)

#医学 #研究 #実験

進行性唾液腺癌に対するCisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) のレトロスペクティブスタディについての論文

Nakano T, Yasumatsu R, Hashimoto K, Kuga R, Hongo T, Yamamoto H, Matsuo M, Wakasaki T, Jiromaru R, Manako T, **Toh S**, **Masuda M**, Yamauchi M, Kuratomi Y, Uryu H, Nakashima T, Tamae A, Tanaka R, Taura M, Takeuchi T, Yoshida T, Nakagawa T

Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer

In Vivo. 2022 MAR-APR;36(2):979-984.

Journal Impact Factor 2021: 2.406

PMID: 35241559 (<https://pubmed.ncbi.nlm.nih.gov/35241559>) DOI: 10.21873/invivo.12790

(<https://doi.org/10.21873/invivo.12790>) WoS: WOS:000795871700004

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000795871700004>)

#医学 #一般医療 #内科学 #第III相試験 #多施設共同研究 #ランダム化比較試験

小型末梢性非小細胞肺癌に対するセグメント切除術と肺葉切除術の比較 (JCOG0802/WJOG4607L) : 多施設共同、非盲検、第3相、無作為化、対照、非劣性試験についての論文

Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, Aoki T, Okami J, Yoshino I, Ito H, Okumura N, **Yamaguchi M**, Ikeda N, Wakabayashi M, Nakamura K, Fukuda H, Nakamura S, Mitsudomi T, Watanabe SI, Asamura H

Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L) : a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial

Lancet. 2022 APR 23;399(10335):1607-1617.

Journal Impact Factor 2021: 202.731

PMID: 35461558 (<https://pubmed.ncbi.nlm.nih.gov/35461558>) WoS: WOS:000795612300017

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000795612300017>)

#医学 #研究 #実験

ニボルマブ治療を受けた再発・転移性頭頸部扁平上皮がん患者の予後バイオマーカーとしての炎症に基づく予後スコアの検討についての論文

Matsuo M, Yasumatsu R, **Masuda M**, **Toh S**, Wakasaki T, Hashimoto K, Jiromaru R, Manako T, Nakagawa T
Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy

In Vivo. 2022 MAR-APR;36(2):907-917.

Journal Impact Factor 2021: 2.406

PMID: 35241549 (<https://pubmed.ncbi.nlm.nih.gov/35241549>) DOI: 10.21873/invivo.12780

(<https://doi.org/10.21873/invivo.12780>) WoS: WOS:000795786400019

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000795786400019>)

#腫瘍学

骨軟部腫瘍の手術を受ける患者におけるトラネキサム酸の有効性と安全性 : 傾向スコアマッチング法による解析についての論文

Oyama R, **Setzu N**, Matsumoto Y, Endo M, Fujiwara T, Iida K, Nabeshima A, Nakashima Y

Efficacy and safety of tranexamic acid in patients undergoing surgery for bone and soft tissue tumors: a propensity score matching analysis

Jpn J Clin Oncol. 2022 SEP 18;52(9):1029-1038.

Journal Impact Factor 2021: 2.925

PMID: 35532289 (<https://pubmed.ncbi.nlm.nih.gov/35532289>) DOI: 10.1093/jjco/hyac078

(<https://doi.org/10.1093/jjco/hyac078>) WoS: WOS:000792393300001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000792393300001>)

#腫瘍学 #多施設共同研究

抗PD-1単剤治療を受けた非小細胞肺癌患者の転帰に対するスタチン治療の影響に関する傾向スコアマッチ分析 : 多施設共同レトロスペクティブスタディについての論文

Takada K, **Shimokawa M**, **Takamori S**, Shimamatsu S, Hirai F, Tagawa T, **Okamoto T**, Hamatake M, Tsuchiya-Kawano Y, Otsubo K, Inoue K, Yoneshima Y, Tanaka K, Okamoto I, Nakanishi Y, Mori M

A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study
BMC Cancer. 2022 MAY 6;22(1)

Journal Impact Factor 2021: 4.638

PMID: 35524214 (<https://pubmed.ncbi.nlm.nih.gov/35524214>) DOI: 10.1186/s12885-022-09385-8

(<https://doi.org/10.1186/s12885-022-09385-8>) WoS: WOS:000791786100003

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000791786100003>)

#皮膚病学

日本人における基底細胞癌の臨床的境界判定における一致性。JCOG2005の予備調査 (J-BASE-MARGIN) についての論文

Kamimura A, Nakamura Y, Takenouchi T, Matsushita S, Omodaka T, Yamamura K, **Uchi H**, Yoshikawa S, Yanagisawa H, Ito T, Kiyohara Y, Nakamura Y, Aoki M, Ishizuki S, Oashi K, Miyagawa T, Maeda T, Ogata D, Hatta N, Ohe S, Isei T, Takahashi A, Umeda Y, Yamaguchi B, Ishikawa M, Horimoto K, Fujsawa Y, Uehara J, Shibayama Y, Kiniwa Y, Kawahara Y, Matsuya T, Uhara H, Kato J, Nakamura Y, Murakami T, Namikawa K, Yoshino K, Funakoshi T, Takatsuka S, Matsui Y, Sasaki J, Koga H, Yokota K, Komori T, Fukushima S, Yamazaki N

Concordance in judgment of clinical borders of basal cell carcinomas in Japanese patients: A preliminary study of JCOG2005 (J-BASE-MARGIN)

J Dermatol. 2022 SEP;49(9):837-844.

Journal Impact Factor 2021: 3.468

PMID: 35510662 (<https://pubmed.ncbi.nlm.nih.gov/35510662>) DOI: 10.1111/1346-8138.16422

(<https://doi.org/10.1111/1346-8138.16422>) WoS: WOS:000790739300001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000790739300001>)

#腫瘍学

NTRK融合遺伝子陽性の固形がん患者におけるEntrectinibの有効性と安全性に関する統合解析の更新についての論文

Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Lin JJ, Goto K, Lee J, Bazhenova L, John T, Fakih M, Chawla SP, Dziadziuszko R, **Seto T**, Heinzmann S, Pitcher B, Chen D, Wilson TR, Rolfo C

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

Clin Cancer Res. 2022 APR 1;28(7):1302-1312.

Journal Impact Factor 2021: 13.801

PMID: 35144967 (<https://pubmed.ncbi.nlm.nih.gov/35144967>) DOI: 10.1158/1078-0432.CCR-21-3597

(<https://doi.org/10.1158/1078-0432.CCR-21-3597>) WoS: WOS:000787773900001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000787773900001>)

#腫瘍学 #第I相試験 #第II相試験

切除不能又は転移性胃腸膵神経内分泌腫瘍の日本人患者を対象としたストレプトゾシン単剤療法の第I/II相試験についての論文

Komoto I, Kokudo N, Aoki T, Morizane C, Ito T, Hashimoto T, Kimura W, Inoue N, Hasegawa K, Kondo S, Ueno H, Igarashi H, **Oono T**, Makuuchi M, Takamoto T, Hirai I, Takeshita A, Imamura M

Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors

Jpn J Clin Oncol. 2022 JUL 8;52(7):708-716.

Journal Impact Factor 2021: 2.925

PMID: 35411926 (<https://pubmed.ncbi.nlm.nih.gov/35411926>) DOI: 10.1093/jjco/hyac048

(<https://doi.org/10.1093/jjco/hyac048>) WoS: WOS:000785692600001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000785692600001>)

#消化器病学 #肝臓学 #レビュー論文 #システムティックレビュー

表在性食道扁平上皮癌の浸潤深度を診断するための内視鏡画像モダリティ：システムティックレビューについての論文

Inoue T, Ishihara R, Shibata T, Suzuki K, Kitagawa Y, Miyazaki T, Yamaji T, Nemoto K, Oyama T, Muto M, Takeuchi H, **Toh Y**, Matsubara H, Mano M, Kono K, Kato K, Yoshida M, Kawakubo H, Booka E, Yamatsuji T,

Kato H, Ito Y, Ishikawa H, Tsushima T, Kawachi H, Oyama T, Kojima T, Kuribayashi S, Makino T, Matsuda S, Doki Y, Esophageal Canc Practice Guideline

Endoscopic imaging modalities for diagnosing the invasion depth of superficial esophageal squamous cell carcinoma: a systematic review

Esophagus. 2022 JUL;19(3):375-383.

Journal Impact Factor 2021: 3.671

PMID: 35397101 (<https://pubmed.ncbi.nlm.nih.gov/35397101>) DOI: 10.1007/s10388-022-00918-5

(<https://doi.org/10.1007/s10388-022-00918-5>) WoS: WOS:000781280900001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000781280900001>)

#腫瘍学 #多施設共同研究

珍しいEGFR変異を有するNSCLC患者におけるチロシンキナーゼ阻害剤の活性。レトロスペクティブ国際コホート研究 (UpSwinG)についての論文

Popat S, Hsia TC, Hung JY, Jung HA, Shih JY, Park CK, Lee SH, **Okamoto T**, Ahn HK, Lee YC, Sato Y, Lee SS, Mascaux C, Daoud H, Märten A, Miura S

Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)

Oncologist. 2022 APR 5;27(4):255-265.

Journal Impact Factor 2021: 5.837

PMID: 35274704 (<https://pubmed.ncbi.nlm.nih.gov/35274704>) DOI: 10.1093/oncolo/oyac022

(<https://doi.org/10.1093/oncolo/oyac022>) WoS: WOS:000778306200004

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000778306200004>)

#外科学

膵管腺癌患者における術前全身的炎症スコアの影響についての論文

Iguchi T, Iseda N, Hirose K, Itoh S, Harada N, Ninomiya M, **Sugimachi K**, Honboh T, Maeda T, Sadanaga N, Matsuura H

Prognostic Impact of the Preoperative Systemic Inflammation Score in Patients With Pancreatic Ductal Adenocarcinoma

Am Surg. 2023 JUN;89(6):2213-2219.

Journal Impact Factor 2021: 1.002

PMID: 35392670 (<https://pubmed.ncbi.nlm.nih.gov/35392670>) DOI: 10.1177/00031348221086782

(<https://doi.org/10.1177/00031348221086782>) WoS: WOS:000780164900001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000780164900001>)

#腫瘍学

進行性消化器癌におけるマイクロサテライト不安定性評価のための血漿ベースジェノタイピングの臨床的妥当性。

SCRUM-Japan GOZILAサブスタディについての論文

Nakamura Y, Okamoto W, Denda T, Nishina T, Komatsu Y, Yuki S, Yasui H, **Esaki T**, Sunakawa Y, Ueno M, Shinozaki E, Matsushashi N, Ohta T, Kato K, Ohtsubo K, Bando H, Hara H, Satoh T, Yamazaki K, Yamamoto Y, Okano N, Terazawa T, Kato T, Oki E, Tsuji A, Horita Y, Hamamoto Y, Kawazoe A, Nakajima H, Nomura S, Mitani R, Yuasa M, Akagi K, Yoshino T

Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy

JCO Precis Oncol. 2022;6

Journal Impact Factor 2021: 5.479

PMID: 35188805 (<https://pubmed.ncbi.nlm.nih.gov/35188805>) DOI: 10.1200/PO.21.00383

(<https://doi.org/10.1200/PO.21.00383>) WoS: WOS:000771048900001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000771048900001>)

#腫瘍学 #多施設共同研究

ER陽性/HER2陰性閉経後乳癌患者における再発後の全生存率に関連する因子：JBCRG-C06 Safari試験のアドホック解析による検討についての論文

Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Takano T, **Tokunaga E**, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H,

Yamashita T, Yotsumoto D, Toi M, Ohno S

Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study

Jpn J Clin Oncol. 2022 MAY 31;52(6):545-553.

Journal Impact Factor 2021: 2.925

PMID: 35296894 (<https://pubmed.ncbi.nlm.nih.gov/35296894>) DOI: 10.1093/jjco/hyac022

(<https://doi.org/10.1093/jjco/hyac022>) WoS: WOS:000770120500001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000770120500001>)

#腫瘍学 #多施設共同研究

実データに基づく進行性尿路上皮がんに対するプラチナ製剤ベースの化学療法からペムブロリズマブへの最適な切替時期。多施設共同レトロスペクティブスタディについての論文

**Furubayashi N, Morokuma F, Tomoda T, Hori Y, Negishi T, Miura A, Komori H, Kuroiwa K, Nakamura M
Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study**

Anticancer Res. 2022 MAR;42(3):1571-1577.

Journal Impact Factor 2021: 2.435

PMID: 35220254 (<https://pubmed.ncbi.nlm.nih.gov/35220254>) DOI: 10.21873/anticancer.15631

(<https://doi.org/10.21873/anticancer.15631>) WoS: WOS:000767352800023

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000767352800023>)

#腫瘍学 #第I相試験

日本人の再発・難治性B細胞リンパ腫患者を対象としたParsaclisib (CITADEL-111)。第Ib相試験についての論文

Fukuhara N, Suehiro Y, Kato H, Kusumoto S, Coronado C, Rappold E, Zhao WY, Li J, Gilmartin A, Izutsu K

Parsaclisib in Japanese patients with relapsed or refractory B-cell lymphoma (CITADEL-111): A phase Ib study

Cancer Sci. 2022 MAY;113(5):1702-1711.

Journal Impact Factor 2021: 6.518

PMID: 35201656 (<https://pubmed.ncbi.nlm.nih.gov/35201656>) DOI: 10.1111/cas.15308

(<https://doi.org/10.1111/cas.15308>) WoS: WOS:000768647100001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000768647100001>)

#医学 #一般医療 #内科学

個室か相部屋か？患者が最期を迎える場所に対する遺族の意識に関する全国アンケート調査についての論文

Otani H, Morita T, Igarashi N, Shima Y, Miyashita M

Private or shared room? A nationwide questionnaire survey on bereaved family members' perceptions of where patients spend their last days

BMJ Open. 2022 MAR;12(3)

Journal Impact Factor 2021: 3.007

PMID: 35241470 (<https://pubmed.ncbi.nlm.nih.gov/35241470>) DOI: 10.1136/bmjopen-2021-055942

(<https://doi.org/10.1136/bmjopen-2021-055942>) WoS: WOS:000765426300013

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000765426300013>)

#外科学 #観察研究

食道扁平上皮癌の術前治療効果および生存率を予測するバイオマーカーとしてのRAD51発現量 大規模コホート観察研究 (KSCC1307) についての論文

Saeki H, Jogo T, Kawazoe T, Kamori T, Nakaji Y, Zaitzu Y, Fujiwara M, Baba Y, Nakamura T, Iwata N, Egashira A, Nakanoko T, Morita M, Tanaka Y, Kimura Y, Shibata T, Nakashima Y, Emi Y, Makiyama A, Oki E, Tokunaga S, Shimokawa M, Mori M, Kyushu Study Grp

RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma A Large-cohort Observational Study (KSCC1307)

Ann Surg. 2022 APR;275(4):692-699.

Journal Impact Factor 2021: 13.787

PMID: 32482981 (<https://pubmed.ncbi.nlm.nih.gov/32482981>) DOI: 10.1097/SLA.0000000000003975

(<https://doi.org/10.1097/SLA.0000000000003975>) WoS: WOS:000766217800025

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000766217800025>)

#腫瘍学 #第I相試験 #第II相試験 #多施設共同研究

LAG-3阻害剤ieramilimab (LAG525) +/-抗PD-1薬spartalizumab (PDR001) の進行性悪性腫瘍患者を対象とした第I/II相臨床試験についての論文

Schöffski P, Tan DSW, Martín M, Ochoa-de-Olza M, Sarantopoulos J, Carvajal RD, Kyi C, **Esaki T**, Prawira A, Akerley W, De Braud F, Hui RN, Zhang T, Soo RA, Maur M, Weickhardt A, Krauss J, Deschler-Baier B, Lau A, Samant TS, Longmire T, Chowdhury NR, Sabatos-Peyton CA, Patel N, Ramesh R, Hu TC, Carion A, Gusenleitner D, Yerramilli-Rao P, Askoxylakis V, Kwak EL, Hong DS

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

J Immunother Cancer. 2022 FEB;10(2)

Journal Impact Factor 2021: 12.485

PMID: 35217575 (<https://pubmed.ncbi.nlm.nih.gov/35217575>) DOI: 10.1136/jitc-2021-003776

(<https://doi.org/10.1136/jitc-2021-003776>) WoS: WOS:000762406500001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000762406500001>)

#心臓 #循環器系

第8版TNMステージングシステムにおける部分固形肺癌の臨床的意義についての論文

Okamoto T, Miyawaki M, Toyokawa G, Karashima T, Abe M, Takumi Y, Hashimoto T, Osoegawa A, Tagawa T, Takeuchi H, **Shimokawa M**, Sugio K

Clinical significance of part-solid lung cancer in the eighth edition TNM staging system

Interact Cardiovasc Thorac Surg. 2022 JAN 18;34(2):219-226.

Journal Impact Factor 2021: 1.978

PMID: 34561707 (<https://pubmed.ncbi.nlm.nih.gov/34561707>) DOI: 10.1093/icvts/ivab255

(<https://doi.org/10.1093/icvts/ivab255>) WoS: WOS:000761453400007

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000761453400007>)

#複合科学

高齢のびまん性大細胞型B細胞リンパ腫患者における有害事象の予測に有用な手段としての包括的老年学的評価についての論文

Tanaka T, Sakai R, **Choi I**, Tsukada J, Sasaki H, Naito Y, Kiyomi F, Takamatsu Y, Tamura K

Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma

Sci Rep. 2022 FEB 24;12(1)

Journal Impact Factor 2021: 4.997

PMID: 35210509 (<https://pubmed.ncbi.nlm.nih.gov/35210509>) DOI: 10.1038/s41598-022-07164-w

(<https://doi.org/10.1038/s41598-022-07164-w>) WoS: WOS:000761303400089

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000761303400089>)

#複合科学

がんの精密ゲノム検査には、すべての関係者が参加する熟練度テストが必要についての論文

Maekawa M, Taniguchi T, Nishio K, Sakai K, Matsushita K, Nakatani K, Ishige T, Ikejiri M, Nishihara H, Sunami K, Yatabe Y, Hatanaka KC, Hatanaka Y, Yamamoto Y, Fukuyama K, **Oda S**, Saito K, Yokomura M, Kubo Y, Sato H, Tanaka Y, Fuchioka M, Yamasaki T, Matsuda K, Kurachi K, Funai K, Baba S, Iwaizumi M

Precision cancer genome testing needs proficiency testing involving all stakeholders

Sci Rep. 2022 JAN 27;12(1)

Journal Impact Factor 2021: 4.997

PMID: 35087199 (<https://pubmed.ncbi.nlm.nih.gov/35087199>) DOI: 10.1038/s41598-022-05589-x

(<https://doi.org/10.1038/s41598-022-05589-x>) WoS: WOS:000749198000021

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000749198000021>)

#消化器病学 #肝臓学

食道癌に対する食道切除術後の胃管癌の臨床病理学的特徴と予後：日本における全国調査についての論文

Ota M, Morita M, Ikebe M, Nakashima Y, Yamamoto M, Matsubara H, Kakeji Y, Doki Y, Toh Y

Clinicopathological features and prognosis of gastric tube cancer after esophagectomy for esophageal cancer: a nationwide study in Japan

Esophagus. 2022 JUL;19(3):384-392.

Journal Impact Factor 2021: 3.671

PMID: 35239079 (<https://pubmed.ncbi.nlm.nih.gov/35239079>) DOI: 10.1007/s10388-022-00915-8

(<https://doi.org/10.1007/s10388-022-00915-8>) WoS: WOS:000763898700001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000763898700001>)

#腫瘍学

同種移植後のT細胞性急性リンパ芽球性白血病の小児および青年の予後因子についての論文

Ishida H, Kato M, Kawahara Y, Ishimaru S, Najima Y, Kako S, Sato M, Hiwatari M, **Noguchi M**, Kato K, Koh K, Okada K, Iwasaki F, Kobayashi R, Igarashi S, Saito S, Takahashi Y, Sato A, Tanaka J, Hashii Y, Atsuta Y, Sakaguchi H, Imamura T

Prognostic factors of children and adolescents with T-cell acute lymphoblastic leukemia after allogeneic transplantation

Hematol Oncol. 2022 AUG;40(3):457-468.

Journal Impact Factor 2021: 4.85

PMID: 35212019 (<https://pubmed.ncbi.nlm.nih.gov/35212019>) DOI: 10.1002/hon.2980

(<https://doi.org/10.1002/hon.2980>) WoS: WOS:000763578000001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000763578000001>)

#腫瘍学 #観察研究

高齢者（75歳以上）の非小細胞肺癌に対する術後補助化学療法に関する前向き観察研究についての論文

Yano T, Hamatake M, Tokunaga S, **Okamoto T**, Yamazaki K, Miura T, Nagayasu T, Sato M, Fukuyama S, Sugio K, Lung Oncology Grp Kyushu LOGIK

A prospective observational study of postoperative adjuvant chemotherapy for non-small cell lung cancer in elderly patients (≥ 75 years)

Int J Clin Oncol. 2022 MAY;27(5):882-888.

Journal Impact Factor 2021: 3.85

PMID: 35212829 (<https://pubmed.ncbi.nlm.nih.gov/35212829>) DOI: 10.1007/s10147-022-02143-7

(<https://doi.org/10.1007/s10147-022-02143-7>) WoS: WOS:000761896000002

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000761896000002>)

#免疫学

日本における子宮頸部上皮内新生物のワクチン未接種女性におけるHPV16/18有病率の変化。HPVワクチン接種プログラム後の集団効果の評価についての論文

Onuki M, Yamamoto K, Yahata H, Kanao H, Horie K, Konnai K, **Nio A**, Takehara K, Kamiura S, Tsuda N, Takei Y, Shigeta S, Nakai H, Yoshida H, Motohara T, Kato T, Nakamura K, Hamanishi J, Tasaka N, Ishikawa M, Kado N, Taira Y, Mori M, Iwata T, Takahashi F, Kukimoto I, Yoshikawa H, Yaegashi N, Matsumoto K, MINT Study Grp

Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program

Vaccines. 2022 FEB;10(2)

Journal Impact Factor 2021: 4.961

PMID: 35214646 (<https://pubmed.ncbi.nlm.nih.gov/35214646>) DOI: 10.3390/vaccines10020188

(<https://doi.org/10.3390/vaccines10020188>) WoS: WOS:000762272300001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000762272300001>)

#腫瘍学 #多施設共同研究

再発・転移性唾液腺がん患者におけるPD-1阻害剤治療の有効性についての論文

Hashimoto K, Yasumatsu R, Kuga R, Hongo T, Yamamoto H, Matsuo M, Wakasaki T, Jiromaru R, Manako T, **Toh S, Masuda M**, Yamauchi M, Kuratomi Y, Uryu H, Nakashima T, Tamae A, Tanaka R, Taura M, Takeuchi T, Yoshida T, Nakagawa T

Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma

Anticancer Res. 2022 FEB;42(2):981-989.

Journal Impact Factor 2021: 2.435

PMID: 35093898 (<https://pubmed.ncbi.nlm.nih.gov/35093898>) DOI: 10.21873/anticancerres.15558

(<https://doi.org/10.21873/anticancerres.15558>) WoS: WOS:000749273700017

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000749273700017>)

#腫瘍学 #多施設共同研究

ゲムシタピン+ナブパクリタキセルまたはFOLFIRINOXによる治療を受けた切除不能膵臓癌患者の予後ノモグラム：日本における多施設共同後ろ向き研究（NAPOLEON試験）のポストホック解析結果についての論文

Shibuki T, Mizuta T, **Shimokawa M**, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Makiyama A, Taguchi H, Honda T, Mitsugi K, Nio K, Ide Y, Ureshino N, Shirakawa T, Otsuka T

Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)

BMC Cancer. 2022 JAN 3;22(1)

Journal Impact Factor 2021: 4.638

PMID: 34980029 (<https://pubmed.ncbi.nlm.nih.gov/34980029>) DOI: 10.1186/s12885-021-09139-y

(<https://doi.org/10.1186/s12885-021-09139-y>) WoS: WOS:000738001600005

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000738001600005>)

#腫瘍学 #多施設共同研究 #観察研究

シスプラチン誘発性腎毒性に対する20mEqおよび8mEqのマグネシウム補給の予防効果：傾向スコアマッチング解析についての論文

Miyoshi T, Hayashi T, **Uoi M**, Omura F, Tsumagari K, Maesaki S, Yokota C, Nakano T, Egawa T

Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score-matched analysis

Support Care Cancer. 2022 APR;30(4):3345-3351.

Journal Impact Factor 2021: 3.359

PMID: 34984552 (<https://pubmed.ncbi.nlm.nih.gov/34984552>) DOI: 10.1007/s00520-021-06790-w

(<https://doi.org/10.1007/s00520-021-06790-w>) WoS: WOS:000738444000001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000738444000001>)

#耳鼻咽喉科学

中咽頭扁平上皮癌の臨床的解析：単一施設の経験からについての論文

Jiromaru R, Yasumatsu R, Yamamoto H, Kuga R, Hongo T, **Nakano T**, Manako T, Hashimoto K, Wakasaki T, Matsuo M, Nakagawa T

A clinical analysis of oropharyngeal squamous cell carcinoma: a single-institution's experience

Eur Arch Oto-Rhino-Laryn. 2022 JUL;279(7):3717-3725.

Journal Impact Factor 2021: 3.236

PMID: 34978590 (<https://pubmed.ncbi.nlm.nih.gov/34978590>) DOI: 10.1007/s00405-021-07236-z

(<https://doi.org/10.1007/s00405-021-07236-z>) WoS: WOS:000737702600001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000737702600001>)

10月～3月

#腫瘍学 #第II相試験 #第I相試験

局所進行子宮頸癌に対する腔内および間質性ブラキセラピー併用療法の第I/II相前向き臨床試験についての論文

Murakami N, Watanabe M, Uno T, Sekii S, Tsujino K, Kasamatsu T, Machitori Y, Aoshika T, Kato S, Hirowatari H, Kaneyasu Y, Nakagawa T, Ikushima H, Ando K, Murata M, Yoshida K, Yoshioka H, Murata K, Ohno T, Okonogi N, Saito A, Ichikawa M, Okuda T, Tsuchida K, Sakurai H, Yoshimura R, Yoshioka Y, Yorozu A, **Kunitake N**, Okamoto H, Inaba K, Kato T, Igaki H, Itami J

Phase I/II prospective clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer

J Gynecol Oncol. 2023 MAY;34(3)

Journal Impact Factor 2021: 4.756

PMID: 36603849 (<https://pubmed.ncbi.nlm.nih.gov/36603849>) DOI: 10.3802/jgo.2023.34.e24
(<https://doi.org/10.3802/jgo.2023.34.e24>) WoS: WOS:001047132900014
(<https://www.webofscience.com/wos/woscc/full-record/WOS:001047132900014>)

#腫瘍学 #多施設共同研究

変異型尿路上皮がん患者におけるペムブロリズマブの有効性：多施設共同レトロスペクティブ研究についての論文

Minato A, **Furubayashi N**, Harada M, **Negishi T**, Sakamoto N, Song Y, Hori Y, Tomoda T, Tamura S, Kuroiwa K, Seki N, Tomisaki I, Harada K, **Nakamura M**, Fujimoto N

Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study

Clin Genitourin Cancer. 2022 OCT;20(5)

Journal Impact Factor 2021: 3.121

PMID: 35624001 (<https://pubmed.ncbi.nlm.nih.gov/35624001>) DOI: 10.1016/j.clgc.2022.05.001
(<https://doi.org/10.1016/j.clgc.2022.05.001>) WoS: WOS:001043904500029
(<https://www.webofscience.com/wos/woscc/full-record/WOS:001043904500029>)

#腫瘍学 #多施設共同研究

高齢の進行性非小細胞肺癌患者における全身療法毒性の予測：国立病院機構による多施設共同前向き研究についての論文

Kanazu M, **Shimokawa M**, Saito R, Mori M, Tamura A, Okano Y, Fujita Y, Endo T, Motegi M, Takata S, Kita T, Sukoh N, **Takenoyama M**, Atagi S

Predicting systemic therapy toxicity in older adult patients with advanced non-small cell lung cancer: A prospective multicenter study of National Hospital Organization in Japan

J Geriatr Oncol. 2022 NOV;13(8):1216-1222.

Journal Impact Factor 2021: 3.929

PMID: 36008273 (<https://pubmed.ncbi.nlm.nih.gov/36008273>) DOI: 10.1016/j.jgo.2022.07.011
(<https://doi.org/10.1016/j.jgo.2022.07.011>) WoS: WOS:000966250700018
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000966250700018>)

#外科学 #多施設共同研究

切除可能な膵頭部癌患者における膵頭十二指腸切除術後の早期再発の予測因子。多施設共同レトロスペクティブスタディについての論文

Ono S, Adachi T, Ohtsuka T, Kimura R, Nishihara K, Watanabe Y, Nagano H, Tokumitsu Y, Nanashima A, Imamura N, Baba H, Chikamoto A, Inomata M, Hirashita T, **Furukawa M**, Idichi T, Shinchi H, Maruyama Y, Nakamura M, Eguchi S

Predictive factors for early recurrence after pancreaticoduodenectomy in patients with resectable pancreatic head cancer: A multicenter retrospective study

Surgery. 2022 DEC;172(6):1782-1790.

Journal Impact Factor 2021: 4.348

PMID: 36123175 (<https://pubmed.ncbi.nlm.nih.gov/36123175>) DOI: 10.1016/j.surg.2022.08.004
(<https://doi.org/10.1016/j.surg.2022.08.004>) WoS: WOS:000933942300028
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000933942300028>)

#腫瘍学 #ランダム化比較試験 #第II相試験

局所進行膵臓癌に対する修正FOLFIRINOXとゲムシタピン+ナブパクリタキセルの無作為化第II相試験（JCOG1407試験）についての論文

Ozaka M, Nakachi K, Kobayashi S, Ohba A, Imaoka H, Terashima T, Ishii H, Mizusawa J, Katayama H, Kataoka T, Okusaka T, Ikeda M, Sasahira N, Miwa H, Mizukoshi E, Okano N, Mizuno N, Yamamoto T, Komatsu Y, Todaka A, Kamata K, **Furukawa M**, Fujimori N, Katanuma A, Takayama Y, Tsumura H, Fukuda H, Ueno M, Furuse J, Japan Clinical Oncol Grp JCOG

A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)

Eur J Cancer. 2023 MAR;181:135-144.

Journal Impact Factor 2021: 10.002

PMID: 36652891 (<https://pubmed.ncbi.nlm.nih.gov/36652891>) DOI: 10.1016/j.ejca.2022.12.014
(<https://doi.org/10.1016/j.ejca.2022.12.014>) WoS: WOS:000931329300001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000931329300001>)

#腫瘍学 #第II相試験

転移性大腸がん患者における初回化学療法としてのmFOLFOX6/XELOX+bevacizumab併用療法のバイオマーカー探索第II相試験 (WJOG7612GTR試験) についての論文

Okamoto W, Sakai K, Makiyama A, Yamamoto Y, Shitara K, Denda T, Izawa N, Nakano Y, Nishina T, **Esaki T**, Hara H, Miura Y, Boku N, Yamazaki K, Hironaka S, Misumi T, Hyodo I, Muro K, Nishio K

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR) ESMO Open. 2022 DEC;7(6)

Journal Impact Factor 2021: 6.883

PMID: 36502778 (<https://pubmed.ncbi.nlm.nih.gov/36502778>) DOI: 10.1016/j.esmoop.2022.100592
(<https://doi.org/10.1016/j.esmoop.2022.100592>) WoS: WOS:000919613200001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000919613200001>)

#消化器病学 #肝臓学 #多施設共同研究

転移・再発の膵臓扁平上皮癌患者に対する化学療法の有効性：多施設共同レトロスペクティブ解析による検討についての論文

Yoshida Y, Kobayashi S, Ueno M, Morizane C, Tsuji K, Maruki Y, Mori K, Watanabe K, Ohba A, Furuta M, Todaka A, Tsujimoto A, Ozaka M, Okano N, Yane K, Umemoto K, Kawamoto Y, Terashima T, Tsumura H, Doi K, Shioji K, Asagi A, Kojima Y, Suzuki E, Toshiyama R, **Furukawa M, Naganuma A**, Suzuki R, Miwa H, Ikeda M, Furuse J

Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis Pancreatology. 2022 DEC;22(8):1159-1166.

Journal Impact Factor 2021: 3.977

PMID: 36150984 (<https://pubmed.ncbi.nlm.nih.gov/36150984>) DOI: 10.1016/j.pan.2022.09.236
(<https://doi.org/10.1016/j.pan.2022.09.236>) WoS: WOS:000920796100013
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000920796100013>)

#腫瘍学 #ランダム化比較試験

日本人女性卵巣癌患者におけるVeliparibとフロントライン化学療法および維持療法：第3相VELIA試験における有効性、安全性および制吐剤の使用に関するサブ解析についての論文

Mizuno M, Ito K, Nakai H, Kato H, Kamiura S, Ushijima K, Nagao S, Takano H, **Okadome M**, Takekuma M, Tokunaga H, Nagase S, Aoki D, Coleman RL, Nishimura Y, Ratajczak CK, Hashiba H, Xiong H, Katsumata N, Enomoto T, Okamoto A

Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial Int J Clin Oncol. 2023 JAN;28(1):163-174.

Journal Impact Factor 2021: 3.85

PMID: 36534262 (<https://pubmed.ncbi.nlm.nih.gov/36534262>) DOI: 10.1007/s10147-022-02258-x
(<https://doi.org/10.1007/s10147-022-02258-x>) WoS: WOS:000905254100002
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000905254100002>)

#腫瘍学 #多施設共同研究

WJOG13219G：前治療歴のないBRAF (V600E) 変異型転移性大腸がんに対するFOLFOXIRIまたはDoubletと抗VEGF療法の有効性と安全性。多施設共同レジストリベース試験 (BRACELET試験) についての論文

Shimozaki K, Hirata K, Sato T, Nakamura M, Kato K, Hirano H, Kumekawa Y, Hino K, Kawakami K, Kito Y, Matsumoto T, Kawakami T, **Komoda M**, Nagashima K, Sato Y, Yamazaki K, Hironaka S, Takaishi H, Hamamoro Y, Muro K

WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAF^{V600E} Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study)

Clin Colorectal Canc. 2022 DEC;21(4):339-346.

Journal Impact Factor 2021: 4.035

PMID: 36117091 (<https://pubmed.ncbi.nlm.nih.gov/36117091>) DOI: 10.1016/j.clcc.2022.08.002

(<https://doi.org/10.1016/j.clcc.2022.08.002>) WoS: WOS:000902258500007

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000902258500007>)

#腫瘍学

ER陽性/HER2陰性閉経後進行乳癌に対する酢酸メドロキシプロゲステロンの有効性に関するレトロスペクティブスタディ: JBCRG-C06 Safari試験の追加解析結果についての論文

Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, **Tokunaga E**, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto D, Toi M, Ohno S

Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study

Jpn J Clin Oncol. 2023 MAR 7;53(3):203-211.

Journal Impact Factor 2021: 2.925

PMID: 36484305 (<https://pubmed.ncbi.nlm.nih.gov/36484305>) DOI: 10.1093/jjco/hyac184

(<https://doi.org/10.1093/jjco/hyac184>) WoS: WOS:000905066400001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000905066400001>)

#腫瘍学

ネオアジュバント化学放射線療法を施行した食道扁平上皮癌患者に対して胸腔鏡下切除は必要なのか? 日本食道癌総合登録に基づく傾向一致分析についての論文

Oshikiri T, Numasaki H, Oguma J, **Toh Y**, Watanabe M, Muto M, Kakeji Y, Doki Y

Is Thoracic Duct Resection Necessary for Esophageal Squamous Cell Carcinoma Patients Treated with Neoadjuvant Chemoradiotherapy? A Propensity-Matched Analysis Based on the Comprehensive Registry of Esophageal Cancer in Japan

Ann Surg Oncol. 2022 DEC 18;

Journal Impact Factor 2021: 4.339

PMID: 36529778 (<https://pubmed.ncbi.nlm.nih.gov/36529778>) DOI: 10.1245/s10434-022-12891-5

(<https://doi.org/10.1245/s10434-022-12891-5>) WoS: WOS:000900209700002

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000900209700002>)

#複合科学

薬物療法の経過に伴う泌尿器科がん患者の認識と期待の変化についての論文

Satou Y, Ieiri K, Negishi T, Furubayashi N, Nakamura M

Change of genitourinary cancer patients' perception and expectations over the course of pharmacotherapy

PLoS One. 2022 NOV 22;17(11)

Journal Impact Factor 2021: 3.752

PMID: 36413565 (<https://pubmed.ncbi.nlm.nih.gov/36413565>) DOI: 10.1371/journal.pone.0278039

(<https://doi.org/10.1371/journal.pone.0278039>) WoS: WOS:000903522800042

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000903522800042>)

#消化器病学 #肝臓学

食道癌治療切除術後の有効性指標と再発様式からみた食道癌の各領域リンパ節局在における郭清の意義についての論文

Kanemura T, Miyata H, Takeoka T, Sugase T, Sugimura K, Yamashita K, Tanaka K, Makino T, **Ota M**, Yagi K, **Toh Y**, Seto Y, Doki Y

Significance of dissection in each regional lymph-node station of esophageal cancer based on efficacy index and recurrence patterns after curative esophagectomy

Esophagus. 2023 JUL;20(3):402-409.

Journal Impact Factor 2021: 3.671

PMID: 36574141 (<https://pubmed.ncbi.nlm.nih.gov/36574141>) DOI: 10.1007/s10388-022-00977-8

(<https://doi.org/10.1007/s10388-022-00977-8>) WoS: WOS:000904912400001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000904912400001>)

#腫瘍学 #多施設共同研究

転移性膵臓癌におけるオリジナルと修正FOLFIRINOXの多施設共同レトロスペクティブ解析。NAPOLEON試験の結果についての論文

Nakazawa J, Tsuruta N, **Shimokawa M**, Kawahira M, Arima S, Ido A, Koga F, Ueda Y, Komori A, Otsu S, Fukahori M, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Otsuka T, Shirakawa T, Mitsugi K

Multicenter retrospective analysis of original versus modified FOLFIRINOX in metastatic pancreatic cancer: Results of the NAPOLEON study

Oncology. 2023 JAN;101(1):22-31.

Journal Impact Factor 2021: 3.734

PMID: 36195058 (<https://pubmed.ncbi.nlm.nih.gov/36195058>) DOI: 10.1159/000527176

(<https://doi.org/10.1159/000527176>) WoS: WOS:000891686200001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000891686200001>)

#腫瘍学 #第III相試験 #ランダム化比較試験

前治療歴のある進行性肺腺癌に対するゲフィチニブとエルロチニブを比較した第III相ランダム化試験登録患者の全生存期間解析 (WJOG5108LFS試験) についての論文

Katakami N, Yokoyama T, Morita S, **Okamoto T**, Urata Y, Hattori Y, Iwamoto Y, Sato Y, Ikeda N, Takahashi T, Daga H, Oguri T, Fujisaka Y, Nishino K, Sugawara S, Kozuki T, Oki M, Yamamoto N, Nakagawa K

Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS)

Int J Clin Oncol. 2023 JAN;28(1):79-88.

Journal Impact Factor 2021: 3.85

PMID: 36414827 (<https://pubmed.ncbi.nlm.nih.gov/36414827>) DOI: 10.1007/s10147-022-02266-x

(<https://doi.org/10.1007/s10147-022-02266-x>) WoS: WOS:000886431000002

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000886431000002>)

#消化器病学 #肝臓学

実データを用いた肝細胞癌に対するアテゾリズマブ+ベバシズマブ療法後のラムシルマブの有意性についての論文

Shimose S, **Sugimoto R**, Hiraoka A, Tanaka M, Iwamoto H, **Tanaka Y**, Tada F, Ohama H, Niizeki T, Shirono T, Moriyama E, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T

Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data

Hepatol Res. 2023 FEB;53(2):116-126.

Journal Impact Factor 2021: 4.942

PMID: 36316794 (<https://pubmed.ncbi.nlm.nih.gov/36316794>) DOI: 10.1111/hepr.13852

(<https://doi.org/10.1111/hepr.13852>) WoS: WOS:000884219900001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000884219900001>)

#医学 #一般医療 #内科学 #多施設共同研究

進行性肝細胞癌に対するラムシルマブ2次治療後の予後を規定する因子についての論文

Sugimoto R, Motomura K, Oho A, Aratake Y, Ueda A, **Senju T**, **Tanaka Y**, Yada M, Tanaka K, Kuwano A, Morita Y, Nagasawa S, Ooe M, Mutsuki T, Yoshimoto T, Yamashita N, Nakashima M, Hioki T, Koyanagi T, Higuchi N, Nakamura T, Harada S, Tanaka M, Tada S, Satoh T, Uchimura K, Kuniyoshi M, Nakamuta M, Kohjima M, Liver Dis Investigators Network Ky

Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma

Intern Med. 2022;61(21):3157-3164.

Journal Impact Factor 2021: 1.282

PMID: 36328582 (<https://pubmed.ncbi.nlm.nih.gov/36328582>) DOI: 10.2169/internalmedicine.9237-21

(<https://doi.org/10.2169/internalmedicine.9237-21>) WoS: WOS:000884399200001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000884399200001>)

#生化学 #分子生物学

非小細胞肺癌患者における免疫療法中の腸内細菌叢の多様性と特異的組成の解明についての論文

Shoji F, Yamaguchi M, Okamoto M, Takamori S, Yamazaki K, Okamoto T, Maehara Y

Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer

Front Mol Biosci. 2022 OCT 24;9

Journal Impact Factor 2021: 6.113

PMID: 36353732 (<https://pubmed.ncbi.nlm.nih.gov/36353732>) DOI: 10.3389/fmolb.2022.1040424

(<https://doi.org/10.3389/fmolb.2022.1040424>) WoS: WOS:000880625700001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000880625700001>)

#バイオテクノロジー #応用微生物学

高齢でパフォーマンスステータスが不良の進行性尿路上皮がん患者におけるPembrolizumabの好酸球の変化と有効性、安全性についての論文

Furubayashi N, Minato A, Negishi T, Sakamoto N, Song YHY, Hori Y, Tomoda T, Harada M, Tamura S,

Kobayashi H, Wada Y, Kuroiwa K, Seki N, Fujimoto N, Nakamura M

The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status

OncoTargets Ther. 2022;15:1321-1330.

Journal Impact Factor 2021: 4.345

PMID: 36388155 (<https://pubmed.ncbi.nlm.nih.gov/36388155>) DOI: 10.2147/OTT.S389138

(<https://doi.org/10.2147/OTT.S389138>) WoS: WOS:000882459000001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000882459000001>)

#腫瘍学

日本人BRCA1/2変異体保有者におけるALDH2 rs671変異体の乳がん発症への影響なしについての論文

Mori T, Okamoto Y, Mu AF, Ide Y, Yoshimura A, Senda N, Inagaki-Kawata Y, Kawashima M, Kitao H, Tokunaga E, Miyoshi Y, Ohsumi S, Tsugawa K, Ohta T, Katagiri T, Ohtsuru S, Koike K, Ogawa S, Toi M, Iwata H, Nakamura S, Matsuo K, Takata M

Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese BRCA1/2-mutation carriers

Cancer Med. 2023 MAR;12(6):6594-6602.

Journal Impact Factor 2021: 4.711

PMID: 36345163 (<https://pubmed.ncbi.nlm.nih.gov/36345163>) DOI: 10.1002/cam4.5430

(<https://doi.org/10.1002/cam4.5430>) WoS: WOS:000879601400001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000879601400001>)

#腫瘍学

前治療歴のある肺扁平上皮癌に対するNecitumumabとゲムシタピンおよびシスプラチンの併用療法についての論文

Kinoshita F, Oku Y, Takamori S, Fujishita T, Toyozawa R, Ito K, Shoji F, Okamoto T

Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma

Invest New Drugs. 2023 FEB;41(1):168-172.

Journal Impact Factor 2021: 3.651

PMID: 36331673 (<https://pubmed.ncbi.nlm.nih.gov/36331673>) DOI: 10.1007/s10637-022-01312-9

(<https://doi.org/10.1007/s10637-022-01312-9>) WoS: WOS:000878940700004

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000878940700004>)

#腫瘍学 #症例報告

全身性硬化症と乳癌再発を併発した症例におけるCA15-3と間質性肺疾患の進行との関連性。症例報告についての論文

Ohara M, Koi Y, Sasada T, Kajitani K, Mizuno S, Takata A, Okamoto A, Nagata I, Sumita M, Imachi K, Watanabe M, Daimaru Y, Yoshida Y

Association between CA 15-3 and progression of interstitial lung disease in a case of coexisting systemic sclerosis and recurrent breast cancer: A case report

Mol Clin Oncol. 2022 OCT;17(4)

Journal Impact Factor 2021: N/A

PMID: 36157317 (<https://pubmed.ncbi.nlm.nih.gov/36157317>) DOI: 10.3892/mco.2022.2578
(<https://doi.org/10.3892/mco.2022.2578>) WoS: WOS:000883699400001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000883699400001>)

#血液学 #観察研究 #多施設共同研究

造血細胞移植患者におけるSARS-CoV-2 mRNAワクチン接種後の抗体反応不良の予測因子。日本の多施設共同観察研究についての論文

Mori Y, Uchida N, Harada T, Katayama Y, Wake A, Iwasaki H, Eto T, Morishige S, Fujisaki T, Ito Y, Kamimura T, Takahashi T, Imamura Y, Tanimoto K, Ishitsuka K, Sugita J, Kawano N, Tanimoto K, Yoshimoto G, **Choi I**, Hidaka T, Ogawa R, Takamatsu Y, Miyamoto T, Akashi K, Nagafuji K

Predictors of impaired antibody response after SARS-CoV-2 mRNA vaccination in hematopoietic cell transplant recipients: A Japanese multicenter observational study

Am J Hematol. 2023 JAN;98(1):102-111.

Journal Impact Factor 2021: 13.268

PMID: 36260658 (<https://pubmed.ncbi.nlm.nih.gov/36260658>) DOI: 10.1002/ajh.26769

(<https://doi.org/10.1002/ajh.26769>) WoS: WOS:000878245200001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000878245200001>)

#消化器病学 #肝臓学

肝細胞癌における持続的なウイルス応答後の転写因子における持続的なエピジェネティック変化についての論文

Sugimachi K, Araki H, Saito H, Masuda T, Miura F, Inoue K, **Shimagaki T**, Mano Y, Iguchi T, Morita M, Toh Y, Yoshizumi T, Ito T, Mimori K

Persistent epigenetic alterations in transcription factors after a sustained virological response in hepatocellular carcinoma

JGH Open. 2022 DEC;6(12):854-863.

Journal Impact Factor 2021: N/A

PMID: 36514506 (<https://pubmed.ncbi.nlm.nih.gov/36514506>) DOI: 10.1002/jgh3.12833

(<https://doi.org/10.1002/jgh3.12833>) WoS: WOS:000876235700001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000876235700001>)

#腫瘍学 #多施設共同研究

進行胃癌におけるニボルマブによる3次治療以降の化学療法中の病勢進行パターンと予後不良の関連：日本における多施設共同レトロスペクティブ研究についての論文

Aoki M, Kadowaki S, Takahashi N, Suzuki T, Oshima K, Ando T, Yamamoto Y, Kawakami K, Kito Y, Matsumoto T, Shimozaki K, Miyazaki Y, Yamaguchi T, Nagase M, Tamura T, Amanuma Y, **Esaki T**, Miura Y, Akiyoshi K, Baba E, Makiyama A, Negoro Y, Nakashima K, Sugimoto N, Nagashima K, Shoji H, Boku N

Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan

Gastric Cancer. 2023 JAN;26(1):132-144.

Journal Impact Factor 2021: 7.701

PMID: 36316527 (<https://pubmed.ncbi.nlm.nih.gov/36316527>) DOI: 10.1007/s10120-022-01349-y

(<https://doi.org/10.1007/s10120-022-01349-y>) WoS: WOS:000876840400001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000876840400001>)

#泌尿器学 #腎臓学 #多施設共同研究

去勢抵抗性前立腺がんと骨転移を有する患者に対する二塩化ラジウムの実臨床における有効性と安全性。多施設共同研究についての論文

Matsumoto T, Hori Y, Shiota M, Blas L, **Nakamura M**, Seki N, Kuroiwa K, Yokomizo A, Morokuma F, Kiyoshima K, Eto M

Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study

Int J Urol. 2023 FEB;30(2):139-146.

Journal Impact Factor 2021: 2.896

PMID: 36305673 (<https://pubmed.ncbi.nlm.nih.gov/36305673>) DOI: 10.1111/iju.15078

(<https://doi.org/10.1111/iju.15078>) WoS: WOS:000874785900001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000874785900001>)

#腫瘍学 #症例報告

症例報告後天性METエクソン14スキップ変異を有するEGFR変異型肺腺癌患者においてテポチニブ療法がオシメルチニブ耐性を克服することに成功した症例についての論文

Takamori S, Seto T, Yamaguchi M, Kinoshita F, Fujishita T, Ito K, Toyozawa R, Shoji F, Okamoto T
Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation
Front Oncol. 2022 OCT 13;12

Journal Impact Factor 2021: 5.738

PMID: 36313664 (<https://pubmed.ncbi.nlm.nih.gov/36313664>) DOI: 10.3389/fonc.2022.965741

(<https://doi.org/10.3389/fonc.2022.965741>) WoS: WOS:000876458900001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000876458900001>)

#腫瘍学

切除不能な肝細胞癌に対する第一選択療法としてのアテゾリズマブ+ベバシズマブとレンバチニブの有効性と安全性の比較：傾向スコアマッチング解析による検討についての論文

Niizeki T, Tokunaga T, Takami Y, Wada Y, Harada M, Shibata M, Nakao K, Sasaki R, Hirai F, Shakado S, Yoshizumi T, Itoh S, Yatsuhashi H, Bekki S, Ido A, Mawatari S, Honda K, **Sugimoto R, Senju T**, Takahashi H, Kuwashiro T, Maeshiro T, Nakamuta M, Aratake Y, Yamashita T, Otsuka Y, Matsumoto S, Sohda T, Shimose S, Murotani K, Tanaka Y

Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Target Oncol. 2022 NOV;17(6):643-653.

Journal Impact Factor 2021: 4.897

PMID: 36272060 (<https://pubmed.ncbi.nlm.nih.gov/36272060>) DOI: 10.1007/s11523-022-00921-x

(<https://doi.org/10.1007/s11523-022-00921-x>) WoS: WOS:000871158300001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000871158300001>)

#薬理学 #薬学

HER2陽性またはHER2低転移性/切除不能乳癌におけるTrastuzumab DeruxtecanのQT/QTc間隔および薬物動態への影響についての論文

Shimomura A, Takano T, Takahashi S, Sagara Y, Watanabe J, **Tokunaga E**, Shinkai T, Kamio T, Kikumori K, Kamiyama E, Fujisaki Y, Saotome D, Yamashita T

Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer
Clin Pharmacol Ther. 2023 JAN;113(1):160-169.

Journal Impact Factor 2021: 7.051

PMID: 36164935 (<https://pubmed.ncbi.nlm.nih.gov/36164935>) DOI: 10.1002/cpt.2757

(<https://doi.org/10.1002/cpt.2757>) WoS: WOS:000869176300001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000869176300001>)

#医学 #一般医療 #内科学 #多施設共同研究 #観察研究

分子標的治療後に進行した切除不能な肝細胞癌に対するアテゾリズマブ+ベバシズマブ治療に関する多施設共同前向き観察研究についての論文

Sugimoto R, Satoh T, Ueda A, Senju T, Tanaka Y, Yamashita S, Koyanagi T, Kurashige T, Higuchi N, Nakamura T, Tanaka M, Azuma Y, Ohno A, Oho A, Ooe M, Mutsuki T, Uchimura K, Kuniyoshi M, Tada S, Aratake Y, Yoshimoto T, Yamashita N, Harada S, Nakamuta M, Motomura K, Kohjima M, Liver Dis Investigators Network Ky

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study
Medicine (Baltimore). 2022 OCT 7;101(40)

Journal Impact Factor 2021: 1.817

PMID: 36221372 (<https://pubmed.ncbi.nlm.nih.gov/36221372>) DOI: 10.1097/MD.00000000000030871

(<https://doi.org/10.1097/MD.00000000000030871>) WoS: WOS:000865518700039

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000865518700039>)

#整形外科学

足関節の腫瘍および腫瘍様病変を有する患者における術後の臨床的・機能的転帰についての論文

Kokubu Y, Fujiwara T, Nakagawa K, **Setzu N**, Endo M, Fukushi JI, Matsumoto Y, Nakashima Y

Postoperative clinical and functional outcomes in patients with tumor and tumor-like lesion of foot and ankle

J Foot Ankle Res. 2022 OCT 14;15(1)

Journal Impact Factor 2021: 3.05

PMID: 36229823 (<https://pubmed.ncbi.nlm.nih.gov/36229823>) DOI: 10.1186/s13047-022-00582-z

(<https://doi.org/10.1186/s13047-022-00582-z>) WoS: WOS:000867654400001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000867654400001>)

#腫瘍学

肝機能温存型肝細胞癌に対する肝動脈注入化学療法New-FPの臨床的意義についての論文

Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Tani J, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, **Sugimoto R**, Yonezawa T, Tanaka S, Deguchi A, Shimose S, Shirono T, Sakai M, Suzuki H, Moriyama E, Koga H, Torimura T, Kawaguchi T

The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function

Cancers. 2022 OCT;14(19)

Journal Impact Factor 2021: 6.575

PMID: 36230795 (<https://pubmed.ncbi.nlm.nih.gov/36230795>) DOI: 10.3390/cancers14194873

(<https://doi.org/10.3390/cancers14194873>) WoS: WOS:000866691000001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000866691000001>)

#消化器病学 #肝臓学

食道切除術後の原発性気管・気管支壊死。日本全国多施設共同レトロスペクティブスタディについての論文

Sakai M, Saeki H, Sohda M, Korematsu M, Miyata H, Murakami D, Baba Y, Ishii R, Okamoto H, Shibata T, Shirabe K, **Toh Y**, Shiotani A, Japan Broncho-Esophagological Soc

Primary tracheobronchial necrosis after esophagectomy: A nationwide multicenter retrospective study in Japan

Ann Gastroent Surg. 2023 MAR;7(2):236-246.

Journal Impact Factor 2021: 3.583

PMID: 36998306 (<https://pubmed.ncbi.nlm.nih.gov/36998306>) DOI: 10.1002/ags3.12625

(<https://doi.org/10.1002/ags3.12625>) WoS: WOS:000865097800001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000865097800001>)

#心臓 #循環器系

非小細胞肺癌（20mm以下）に対する肺葉下切除術におけるリンパ節郭清と生存率の関係についての論文

Takamori S, Komiya T, Shimokawa M, Powell E

Lymph node dissections and survival in sublobar resection of non-small cell lung cancer ≤ 20 mm

Gen Thorac Cardiovasc Surg. 2023 MAR;71(3):189-197.

Journal Impact Factor 2021: 1.227

PMID: 36178575 (<https://pubmed.ncbi.nlm.nih.gov/36178575>) DOI: 10.1007/s11748-022-01876-6

(<https://doi.org/10.1007/s11748-022-01876-6>) WoS: WOS:000862197800002

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000862197800002>)

#血液学 #第I相試験 #第II相試験

日本人再発・難治性低悪性度非ホジキンリンパ腫患者に対するコパンリシブの安全性と抗腫瘍活性：第Ib/II相試験についての論文

Fukuhara N, Maruyama D, Hatake K, Nagai H, Makita S, Kamezaki K, Uchida T, Kusumoto S, Kuroda J, Iriyama C, Yanada M, Tsukamoto N, **Suehiro Y**, Minami H, Garcia-Vargas J, Childs BH, Yasuda M, Masuda S, Tsujino T, Terao Y, Tobinai K

Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study

Int J Hematol. 2023 JAN;117(1):100-109.

Journal Impact Factor 2021: 2.324

PMID: 36175779 (<https://pubmed.ncbi.nlm.nih.gov/36175779>) DOI: 10.1007/s12185-022-03455-0

(<https://doi.org/10.1007/s12185-022-03455-0>) WoS: WOS:000863139400001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000863139400001>)

#腫瘍学

放射線治療を行わない乳房温存手術後の同側乳房腫瘍再発に対して5mm間隔スライスと5mmマージンフリー法を用いた2つの研究のプロスペクティブな解析についての論文

Ohsumi S, Nishimura R, Masuda N, Akashi-Tanaka S, Suemasu K, Yamauchi H, **Tokunaga E**, Ikeda T, Nishi T, Hayashi H, Iino Y, Takatsuka Y, Ohashi Y, Inaji H

A prospective analysis of two studies that used the 5-mm interval slices and 5-mm margin-free method for ipsilateral breast tumor recurrence after breast-conserving surgery without radiotherapy

Breast Cancer. 2023 JAN;30(1):131-138.

Journal Impact Factor 2021: 3.307

PMID: 36175750 (<https://pubmed.ncbi.nlm.nih.gov/36175750>) DOI: 10.1007/s12282-022-01406-5

(<https://doi.org/10.1007/s12282-022-01406-5>) WoS: WOS:000863237700001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000863237700001>)

#消化器病学 #肝臓学

日本の食道癌の包括的な登録、2015年についての論文

Watanabe M, **Toh Y**, Ishihara R, Kono K, Matsubara H, Miyazaki T, **Morita M**, Murakami K, Muro K, Numasaki H, Oyama T, Saeki H, Tanaka K, Tsushima T, Ueno M, Uno T, Yoshio T, Usune S, Takahashi A, Miyata H, Japan Esophageal Soc

Comprehensive registry of esophageal cancer in Japan, 2015

Esophagus. 2023 JAN;20(1):1-28.

Journal Impact Factor 2021: 3.671

PMID: 36152081 (<https://pubmed.ncbi.nlm.nih.gov/36152081>) DOI: 10.1007/s10388-022-00950-5

(<https://doi.org/10.1007/s10388-022-00950-5>) WoS: WOS:000857811300001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000857811300001>)

#消化器病学 #肝臓学

日本版ナショナルクリニカルデータベースに登録された高齢食道癌患者における手術死亡の必須危険因子についての論文

Murakami K, Akutsu Y, Miyata H, **Toh Y**, Toyozumi T, Kakeji Y, Seto Y, Matsubara H

Essential risk factors for operative mortality in elderly esophageal cancer patients registered in the National Clinical Database of Japan

Esophagus. 2023 JAN;20(1):39-47.

Journal Impact Factor 2021: 3.671

PMID: 36125625 (<https://pubmed.ncbi.nlm.nih.gov/36125625>) DOI: 10.1007/s10388-022-00957-y

(<https://doi.org/10.1007/s10388-022-00957-y>) WoS: WOS:000857925200001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000857925200001>)

#老年医学 #老年学

包括的な老年医学評価。日本人高齢者がん患者における評価と患者嗜好の検討についての論文

Nishijima TF, Shimokawa M, Esaki T, Morita M, **Toh Y**, Muss HB

Comprehensive geriatric assessment: Valuation and patient preferences in older Japanese adults with cancer

J Am Geriatr Soc. 2023 JAN;71(1):259-267.

Journal Impact Factor 2021: 7.538

PMID: 36112729 (<https://pubmed.ncbi.nlm.nih.gov/36112729>) DOI: 10.1111/jgs.18023

(<https://doi.org/10.1111/jgs.18023>) WoS: WOS:000854266400001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000854266400001>)

#腫瘍学 #レビュー論文

免疫チェックポイント阻害剤で治療した転移性腎細胞がん患者における複数の転移病巣間の反応のばらつきについての論文

Negishi T, Nakagawa T, Nishiyama N, Kitamura H, Okajima E, **Furubayashi N**, Hori Y, Kuroiwa K, Son Y, Seki N, Tomoda T, **Nakamura M**

Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors

Jpn J Clin Oncol. 2022 DEC 5;52(12):1430-1435.

Journal Impact Factor 2021: 2.925

PMID: 36093731 (<https://pubmed.ncbi.nlm.nih.gov/36093731>) DOI: 10.1093/jjco/hyac144

(<https://doi.org/10.1093/jjco/hyac144>) WoS: WOS:000852704800001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000852704800001>)

#腫瘍学

非小細胞肺癌におけるアテゾリズマブベースの免疫療法の有効性に関する腸内細菌群の時系列解析。多施設共同前向き観察研究プロトコルについての論文

Shoji F, Miura N, Tagawa T, Tsukamoto S, **Okamoto T**, Yamazaki K, Hamatake M, Takeo S

Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study

Thorac Cancer. 2022 OCT;13(19):2829-2833.

Journal Impact Factor 2021: 3.223

PMID: 36063818 (<https://pubmed.ncbi.nlm.nih.gov/36063818>) DOI: 10.1111/1759-7714.14640

(<https://doi.org/10.1111/1759-7714.14640>) WoS: WOS:000850171000001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000850171000001>)

#腫瘍学 #観察研究

前治療歴のある非小細胞肺癌患者とその介護者における予後に関する意識と不治の病に関する議論。前向きコホート研究についての論文

Hasegawa T, Okuyama T, Uemura T, Matsuda Y, **Otani H**, Shimizu J, Horio Y, Watanabe N, Yamaguchi T, Fukuda S, Oguri T, Maeno K, Tamiya A, **Nosaki K**, Fukumitsu K, Akechi T

Prognostic Awareness and Discussions of Incurability in Patients with Pretreated Non-Small Cell Lung Cancer and Caregivers: A Prospective Cohort Study

Oncologist. 2022 NOV 3;27(11):982-990.

Journal Impact Factor 2021: 5.837

PMID: 36067268 (<https://pubmed.ncbi.nlm.nih.gov/36067268>) DOI: 10.1093/oncolo/oyac178

(<https://doi.org/10.1093/oncolo/oyac178>) WoS: WOS:000850288700001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000850288700001>)

#腫瘍学 #レビュー論文

原発不明がんに対する部位別治療と経験的治療の比較による多施設共同レトロスペクティブ研究についての論文

Nishikawa K, Hironaka S, Inagaki T, Komori A, Otsu S, Mitsugi K, Makiyama A, Watanabe K, Tamura S, Okumura Y, Kusaba H, **Esaki T**, Baba E, Shirao K

A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site

Jpn J Clin Oncol. 2022 DEC 5;52(12):1416-1422.

Journal Impact Factor 2021: 2.925

PMID: 36047806 (<https://pubmed.ncbi.nlm.nih.gov/36047806>) DOI: 10.1093/jjco/hyac143

(<https://doi.org/10.1093/jjco/hyac143>) WoS: WOS:000848282500001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000848282500001>)

#腫瘍学 #多施設共同研究 #第II相試験

チロシンキナーゼ阻害剤未使用のALK陽性非小細胞肺癌患者に対するブリガチニブの投与：第2相J-ALTA試験の初回結果についての論文

Sugawara S, Kondo M, Yokoyama T, Kumagai T, Nishio M, Goto K, Nakagawa K, **Seto T**, Yamamoto N, Kudou K, Asato T, Zhang PK, Ohe Y

Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study

Int J Clin Oncol. 2022 DEC;27(12):1828-1838.

Journal Impact Factor 2021: 3.85

PMID: 36036294 (<https://pubmed.ncbi.nlm.nih.gov/36036294>) DOI: 10.1007/s10147-022-02232-7

(<https://doi.org/10.1007/s10147-022-02232-7>) WoS: WOS:000847290000001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000847290000001>)

#血液学

小児患者における非血縁者間骨髄移植後の転帰に対するヒト白血球抗原のミスマッチの影響。JSTCT HLAワーキンググループによるレトロスペクティブな解析についての論文

Kato I, Sakaguchi H, Kato S, Sato M, **Noguchi M**, Yoshida N, Koh K, Koike T, Yanagimachi M, Kato K, Takahashi Y, Fujita N, Sato A, Hashii Y, Tabuchi K, Atsuta Y, Morishima S, Kanda J

Impact of human leukocyte antigen mismatch on outcomes after unrelated bone marrow transplantation in paediatric patients: A retrospective analysis by the JSTCT HLA working group

Br J Haematol. 2022 NOV;199(3):392-400.

Journal Impact Factor 2021: 8.615

PMID: 36029121 (<https://pubmed.ncbi.nlm.nih.gov/36029121>) DOI: 10.1111/bjh.18425

(<https://doi.org/10.1111/bjh.18425>) WoS: WOS:000846463300001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000846463300001>)

#腫瘍学 #観察研究

高齢者の切除不能膵臓癌におけるゲムシタピン+Nab-Paclitaxelとゲムシタピン単独の有効性・安全性の比較検討についての論文

Kobayashi S, Suzuki M, Ueno M, Maruki Y, Okano N, Todaka A, Ozaka M, Tsuji K, Shioji K, Doi K, Kojima Y, Tsumura H, Tanaka K, Higuchi H, Kawabe K, Imaoka H, Yamashita T, Miwa H, Nagano H, Arima S, Hayashi H, Naganuma A, Yamaguchi H, **Hisano T**, Umemoto K, Ishii S, Nakashima K, Suzuki R, Kitano Y, Misumi T, Furuse J, Ishii H

Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer

Oncologist. 2022 OCT 1;27(10):E774-E782.

Journal Impact Factor 2021: 5.837

PMID: 35946841 (<https://pubmed.ncbi.nlm.nih.gov/35946841>) DOI: 10.1093/oncolo/oyac157

(<https://doi.org/10.1093/oncolo/oyac157>) WoS: WOS:000838812300001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000838812300001>)

#腫瘍学

日本人子宮頸部上皮内新生物女性におけるヒトパピローマウイルス52型の有病率の地域差 (短剣). についての論文

Kukimoto I, Onuki M, Yamamoto K, Yahata H, Aoki Y, Yokota H, Konnai K, **Nio A**, Takehara K, Kamiura S, Tsuda N, Takei Y, Shimada M, Nakai H, Yoshida H, Motohara T, Yamazaki H, Nakamura K, Okunomiya A, Tasaka N, Ishikawa M, Hirashima Y, Shimoji Y, Mori M, Iwata T, Takahashi F, Yoshikawa H, Yaegashi N, Matsumoto K, MINT Study Grp

Regional differences in human papillomavirus type 52 prevalence among Japanese women with cervical intraepithelial neoplasia[†]

Jpn J Clin Oncol. 2022 OCT 6;52(10):1242-1247.

Journal Impact Factor 2021: 2.925

PMID: 35938523 (<https://pubmed.ncbi.nlm.nih.gov/35938523>) DOI: 10.1093/jjco/hyac127

(<https://doi.org/10.1093/jjco/hyac127>) WoS: WOS:000837163600001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000837163600001>)

#腫瘍学

2018年FIGOステージIB-IIA子宮頸癌の予後因子で、高/中手術病理学的危険因子がないものについての論文

Shibuya Y, Shimada M, Tsuji K, Shigeta S, Tanase Y, Matsuo K, Yamaguchi S, Kanao H, **Saito T**, Mikami M

Prognostic factors of 2018 FIGO stage IB-IIA cervical cancer with absence of high/ intermediate surgical-pathological risk factors

Jpn J Clin Oncol. 2022 NOV 3;52(11):1289-1296.

Journal Impact Factor 2021: 2.925

PMID: 35913375 (<https://pubmed.ncbi.nlm.nih.gov/35913375>) DOI: 10.1093/jjco/hyac125

(<https://doi.org/10.1093/jjco/hyac125>) WoS: WOS:000834283600001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000834283600001>)

#消化器病学 #肝臓学

髄膜神経内分泌腫瘍：臨床病理学的特徴と新規内視鏡的病変の検討についての論文

Matsumoto K, Fujimori N, Hata Y, Minoda Y, Murakami M, Teramatsu K, Takamatsu Y, Takeno A, Oono T, Ihara E, Nakata K, Nakamura M, Yamamoto T, **Koga Y**, Oda Y, Ito T, Ogawa Y

Ampullary Neuroendocrine Neoplasm: Clinicopathological Characteristics and Novel Endoscopic Entity

Dig Dis. 2023 MAR;41(2):316-324.

Journal Impact Factor 2021: 3.421

PMID: 35588707 (<https://pubmed.ncbi.nlm.nih.gov/35588707>) DOI: 10.1159/000525013

(<https://doi.org/10.1159/000525013>) WoS: WOS:000832879200001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000832879200001>)

#血液学 #第I相試験

日本における再発・難治性のCD22陽性急性リンパ性白血病の小児患者を対象としたinotuzumab ozogamicin単剤での第I相試験 (INO-Ped-ALL-1) についての論文

Nakayama H, Ogawa C, Sekimizu M, Fujisaki H, Kosaka Y, Hashimoto H, Saito AM, Horibe K

A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)

Int J Hematol. 2022 OCT;116(4):612-621.

Journal Impact Factor 2021: 2.324

PMID: 35635686 (<https://pubmed.ncbi.nlm.nih.gov/35635686>) DOI: 10.1007/s12185-022-03388-8

(<https://doi.org/10.1007/s12185-022-03388-8>) WoS: WOS:000802911200001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000802911200001>)

#消化器病学 #肝臓学

オキサリプラチンによる肝障害に関連する単純な全身性指標は、大腸肝転移切除後の予後を予測する新規バイオマーカーとなりうることについての論文

Shimagaki T, Sugimachi K, Mano Y, Onishi E, Iguchi T, Uehara H, Sugiyama M, Yamamoto M, Morita M, Toh Y

Simple systemic index associated with oxaliplatin-induced liver damage can be a novel biomarker to predict prognosis after resection of colorectal liver metastasis

Ann Gastroent Surg. 2022 NOV;6(6):813-822.

Journal Impact Factor 2021: 3.583

PMID: 36338597 (<https://pubmed.ncbi.nlm.nih.gov/36338597>) DOI: 10.1002/ags3.12580

(<https://doi.org/10.1002/ags3.12580>) WoS: WOS:000802054500001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000802054500001>)

#腫瘍学

日本全国がんゲノム・スクリーニング・プロジェクト (SCRUM-Japan GI-SCREEN) における転移性大腸がんの NOTCH遺伝子変化についての論文

Kajiwarra T, Nishina T, Nakasya A, Yamashita N, Yamashita R, Nakamura Y, Shiozawa M, Yuki S, Taniguchi H, Hara H, Ohta T, **Esaki T**, Shinozaki E, Takashima A, Moriwaki T, Denda T, Ohtsubo K, Sunakawa Y, Horita Y, Kawakami H, Kato T, Satoh T, Ando K, Mizutani T, Yasui H, Goto M, Okuyama H, Yamazaki K, Yoshino T, Hyodo I

NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN)

J Cancer Res Clin Oncol. 2022 OCT;148(10):2841-2854.

Journal Impact Factor 2021: 4.322

PMID: 35622165 (<https://pubmed.ncbi.nlm.nih.gov/35622165>) DOI: 10.1007/s00432-022-04064-4

(<https://doi.org/10.1007/s00432-022-04064-4>) WoS: WOS:000800703000001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000800703000001>)

#血液学

ベンダムスチンとリツキシマブの併用化学療法を受けている濾胞性リンパ腫患者における血清免疫グロブリンGの感染症判別因子としての役割についての論文

Hirata A, Miyashita K, Tanaka T, Hirata K, Narazaki T, Utsunomiya H, Ohno H, Nakashima E, Tachikawa Y, Choi I, Taguchi K, Suehiro Y

Serum immunoglobulin G as a discriminator of infection in follicular lymphoma patients undergoing chemotherapy with bendamustine in combination with rituximab

Hematology. 2022 DEC 31;27(1):384-395.

Journal Impact Factor 2021: 2.264

PMID: 35344477 (<https://pubmed.ncbi.nlm.nih.gov/35344477>) DOI: 10.1080/16078454.2022.2051863

(<https://doi.org/10.1080/16078454.2022.2051863>) WoS: WOS:000773721600001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000773721600001>)

#腫瘍学

節外性ナチュラルキラーT細胞リンパ腫の長期予後と中枢神経系再発についての論文

Miyazaki K, Suzuki R, Oguchi M, Taguchi S, Amaki J, Maeda T, Kubota N, Maruyama D, Terui Y, Sekiguchi N, Takizawa J, Tsukamoto H, Murayama T, Ando T, Matsuoka H, Hasegawa M, Wada H, Sakai R, Kameoka Y, Tsukamoto N, Choi I, Masaki Y, Shimada K, Fukuhara N, Utsumi T, Uoshima N, Kagami Y, Asano N, Ejima Y, Katayama N, Yamaguchi M

Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma

Hematol Oncol. 2022 OCT;40(4):667-677.

Journal Impact Factor 2021: 4.85

PMID: 35142384 (<https://pubmed.ncbi.nlm.nih.gov/35142384>) DOI: 10.1002/hon.2977

(<https://doi.org/10.1002/hon.2977>) WoS: WOS:000762969600001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000762969600001>)

#腫瘍学 #多施設共同研究

腹膜腔細胞診が陽性の切除可能な膵臓癌の術後治療。多施設共同レトロスペクティブスタディについての論文

Todaka A, Nara S, Motoi F, Morinaga S, Toshiyama R, Higuchi R, Konishi M, Shirakawa H, Tsumura H, Okuyama H, Nagano H, Shioji K, Sugimachi K, Asagi A, Mizuno N, Furuse J

Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study

Anticancer Res. 2022 FEB;42(2):893-902.

Journal Impact Factor 2021: 2.435

PMID: 35093887 (<https://pubmed.ncbi.nlm.nih.gov/35093887>) DOI: 10.21873/anticancer.15547

(<https://doi.org/10.21873/anticancer.15547>) WoS: WOS:000749273700006

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000749273700006>)

#血液学 #臨床試験

フィラデルフィア染色体陽性急性リンパ芽球性白血病の成人患者に対するダサチニブを用いた2段階導入療法についての論文

Sugiura I, Doki N, Hata T, Cho R, Ito T, Suehiro Y, Tanaka M, Kako S, Matsuda M, Yokoyama H, Ishikawa Y, Taniguchi Y, Hagihara M, Ozawa Y, Ueda Y, Hirano D, Sakura T, Tsuji M, Kamae T, Fujita H, Hiramoto N, Onoda M, Fujisawa S, Hatta Y, Dobashi N, Nishiwaki S, Atsuta Y, Kobayashi Y, Hayakawa F, Ohtake S, Naoe T, Miyazaki Y

Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

Blood Adv. 2022 JAN 25;6(2):624-636.

Journal Impact Factor 2021: 7.642

PMID: 34516628 (<https://pubmed.ncbi.nlm.nih.gov/34516628>) DOI: 10.1182/bloodadvances.2021004607 (<https://doi.org/10.1182/bloodadvances.2021004607>) WoS: WOS:000754639300007 (<https://www.webofscience.com/wos/woscc/full-record/WOS:000754639300007>)

#腫瘍学 #観察研究

高齢者の進行非直腸癌におけるCancer and Aging Research Groupスコアと治療強度が生存率と毒性アウトカムに与える影響についての論文

Nishijima TF, Deal AM, Williams GR, Sanoff HK, Nyrop KA, Muss HB

Impact of the Cancer and Aging Research Group score and treatment intensity on survival and toxicity outcomes in older adults with advanced noncolorectal gastrointestinal cancers

Cancer. 2022 MAY 15;128(10):1929-1936.

Journal Impact Factor 2021: 6.921

PMID: 35147991 (<https://pubmed.ncbi.nlm.nih.gov/35147991>) DOI: 10.1002/cncr.34135

(<https://doi.org/10.1002/cncr.34135>) WoS: WOS:000753973300001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000753973300001>)

#腫瘍学 #ランダム化比較試験

HER2陽性転移性乳がん患者におけるPF-05280014（トラスツズマブ・バイオシミラー）治療の長期安全性と有効性。無作為化二重盲検試験の最新結果についての論文

Li RK, Tokunaga E, Adamchuk H, Vladimirov V, Yanez E, Lee KS, Bondarenko I, Vana A, Hilton F, Ishikawa T, Tajima K, Lipatov O

Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study

Biodrugs. 2022 JAN;36(1):55-69.

Journal Impact Factor 2021: 7.744

PMID: 35133617 (<https://pubmed.ncbi.nlm.nih.gov/35133617>) DOI: 10.1007/s40259-021-00513-7

(<https://doi.org/10.1007/s40259-021-00513-7>) WoS: WOS:000752763300001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000752763300001>)

#腫瘍学

日本人女性における初回接種年齢別のHuman Papillomavirusワクチンの有効性についての論文

Onuki M, Yamamoto K, Yahata H, Kanao H, Yokota H, Kato H, Shimamoto K, Takehara K, Kamiura S, Tsuda N, Takei Y, Shigeta S, Matsumura N, Yoshida H, Motohara T, Watari H, Nakamura K, Ueda A, Tasaka N, Ishikawa M, Hirashima Y, Kudaka W, Taguchi A, Iwata T, Takahashi F, Kukimoto I, Yoshikawa H, Yaegashi N, Matsumoto K, MINT Study Grp

Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women

Cancer Sci. 2022 APR;113(4):1428-1434.

Journal Impact Factor 2021: 6.518

PMID: 35043515 (<https://pubmed.ncbi.nlm.nih.gov/35043515>) DOI: 10.1111/cas.15270

(<https://doi.org/10.1111/cas.15270>) WoS: WOS:000750248500001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000750248500001>)

#腫瘍学 #第II相試験

PD-L1高発現の非扁平上皮型非小細胞肺癌に対するatezolizumabとbevacizumabの第II相試験 (@Be Study)についての論文

Seto T, Nosaki K, Shimokawa M, Toyozawa R, Sugawara S, Hayashi H, Murakami H, Kato T, Niho S, Saka H, Oki M, Yoshioka H, Okamoto I, Daga H, Azuma K, Tanaka H, Nishino K, Tohnai R, Yamamoto N, Nakagawa K

Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)

J Immunother Cancer. 2022 FEB;10(2)

Journal Impact Factor 2021: 12.485

PMID: 35105689 (<https://pubmed.ncbi.nlm.nih.gov/35105689>) DOI: 10.1136/jitc-2021-004025

(<https://doi.org/10.1136/jitc-2021-004025>) WoS: WOS:000750204000001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000750204000001>)

#複合科学

高齢者進行胆道癌患者における併用化学療法の臨床成績：JCOG1113の探索的解析についての論文

Yamada I, Morizane C, Okusaka T, Mizusawa J, Kataoka T, Ueno M, Ikeda M, Okano N, Todaka A, Shimizu S, Mizuno N, Sekimoto M, Tobimatsu K, Yamaguchi H, Nishina T, Shirakawa H, Kojima Y, Oono T, Kawamoto Y, **Furukawa M**, Iwai T, Sudo K, Okamura K, Yamashita T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J, JCOG HBPOG

The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113

Sci Rep. 2022 JAN 19;12(1)

Journal Impact Factor 2021: 4.997

PMID: 35046457 (<https://pubmed.ncbi.nlm.nih.gov/35046457/>) DOI: 10.1038/s41598-021-04550-8

(<https://doi.org/10.1038/s41598-021-04550-8>) WoS: WOS:000744620600064

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000744620600064>)

#産科学 #婦人科学 #症例報告

経皮的カテーテルドレナージによる偶発的な嚢胞内出血の後、大きな骨盤リンパ節が解消された一例。症例報告についての論文

Nio A, Okadome M, Shimamoto K, Sonoda K, Saito T

Resolution of large pelvic lymphocele after incidental intracystic hemorrhage caused by percutaneous catheter drainage: Case report

J Obstet Gynaecol Res. 2022 APR;48(4):1050-1054.

Journal Impact Factor 2021: 1.697

PMID: 35108750 (<https://pubmed.ncbi.nlm.nih.gov/35108750/>) DOI: 10.1111/jog.15178

(<https://doi.org/10.1111/jog.15178>) WoS: WOS:000749894800001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000749894800001>)

#消化器病学 #肝臓学 #多施設共同研究

B型慢性肝炎患者に対するtenofovir alafenamideによるHBVの順次投与：実施設における96週目の結果についての論文

Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, **Sugimoto R**, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J, Kyushu Univ Liver Dis Study KULDS

Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study

Hepatol Int. 2022 APR;16(2):282-293.

Journal Impact Factor 2021: 9.046

PMID: 35075593 (<https://pubmed.ncbi.nlm.nih.gov/35075593/>) DOI: 10.1007/s12072-021-10295-3

(<https://doi.org/10.1007/s12072-021-10295-3>) WoS: WOS:000746295900001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000746295900001>)

#腫瘍学 #多施設共同研究

緩和的鎮静療法の家族経験：比例的 vs 持続的深部鎮静法についての論文

Imai K, Morita T, Mori M, Yokomichi N, Yamauchi T, Miwa S, Inoue S, Naito AS, Masukawa K, Kizawa Y, Tsuneto S, Shima Y, **Otani H**, Miyashita M

Family experience of palliative sedation therapy: proportional vs. continuous deep sedation

Support Care Cancer. 2022 MAY;30(5):3903-3915.

Journal Impact Factor 2021: 3.359

PMID: 35039967 (<https://pubmed.ncbi.nlm.nih.gov/35039967/>) DOI: 10.1007/s00520-021-06745-1

(<https://doi.org/10.1007/s00520-021-06745-1>) WoS: WOS:000744402900001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000744402900001>)

#病理学

膵臓粘液性嚢胞新生物の悪性化予測因子としてのRN43についての論文

Sakihama K, **Koga Y**, Yamamoto T, Shimada Y, Yamada Y, Kawata J, Shindo K, Nakamura M, Oda Y

RNF43 as a predictor of malignant transformation of pancreatic mucinous cystic neoplasm
Virchows Arch. 2022 JUN;480(6):1189-1199.

Journal Impact Factor 2021: 4.548

PMID: 35066614 (<https://pubmed.ncbi.nlm.nih.gov/35066614>) DOI: 10.1007/s00428-022-03277-9
(<https://doi.org/10.1007/s00428-022-03277-9>) WoS: WOS:000745562500001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000745562500001>)

#腫瘍学 #臨床試験

臨床病期I期の食道扁平上皮癌患者における予後バイオマーカー研究：JCOG0502-A1についての論文

Oshima K, Kato K, Ito Y, Daiko H, Nozaki I, Nakagawa S, Shibuya Y, Kojima T, **Toh Y**, Okada M, Hironaka S, Akiyama Y, Komatsu Y, Maejima K, Nakagawa H, Onuki R, Nagai M, Kato M, Kanato K, Kuchiba A, Nakamura K, Kitagawa Y

Prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502-A1

Cancer Sci. 2022 MAR;113(3):1018-1027.

Journal Impact Factor 2021: 6.518

PMID: 34962019 (<https://pubmed.ncbi.nlm.nih.gov/34962019>) DOI: 10.1111/cas.15251
(<https://doi.org/10.1111/cas.15251>) WoS: WOS:000740862800001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000740862800001>)

#医学 #研究 #実験 #症例報告

骨転移を有する腎粘液性尿細管癌と紡錘細胞癌に対するニボルマブ+イピリムマブ併用療法後の減量腎切開術。症例報告についての論文

Furubayashi N, Taguchi K, Negishi T, Miura A, Sato Y, Miyoshi M, Nakamura M

Cytoreductive Nephrectomy After Combination of Nivolumab Plus Ipilimumab for Mucinous Tubular and Spindle Cell Carcinoma of the Kidney With Bone Metastases: A Case Report

In Vivo. 2022 JAN-FEB;36(1):510-521.

Journal Impact Factor 2021: 2.406

PMID: 34972756 (<https://pubmed.ncbi.nlm.nih.gov/34972756>) DOI: 10.21873/invivo.12732
(<https://doi.org/10.21873/invivo.12732>) WoS: WOS:000740682300001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000740682300001>)

#呼吸器系 #メタアナリシス

局所進行非小細胞肺癌に対するシスプラチン+S-1併用化学放射線療法とシスプラチン+他の第3世代薬剤の併用療法：参加者個人データのメタ解析結果についての論文

Taniguchi Y, Okamoto H, Shimokawa T, Sasaki T, **Seto T**, Niho S, Ohe Y, Saigusa Y

Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin plus other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data
BMC Pulm Med. 2022 JAN 9;22(1)

Journal Impact Factor 2021: 3.32

PMID: 35000608 (<https://pubmed.ncbi.nlm.nih.gov/35000608>) DOI: 10.1186/s12890-022-01828-z
(<https://doi.org/10.1186/s12890-022-01828-z>) WoS: WOS:000740613000003
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000740613000003>)

#血液学

成人T細胞白血病/リンパ腫に対するモガムリズマブ治療の臨床結果に影響を及ぼすゲノム決定要因についての論文

Tanaka N, Mori S, Kiyotani K, Ota Y, Gotoh O, Kusumoto S, Nakano N, **Suehiro Y**, Ito A, **Choi I**, Ohtsuka E, Hidaka M, Nosaka K, Yoshimitsu M, Imaizumi Y, Iida S, Utsunomiya A, Noda T, Nishikawa H, Ueda R, Ishida T

Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma

Haematologica. 2022 OCT;107(10):2418-2431.

Journal Impact Factor 2021: 11.049

PMID: 35417939 (<https://pubmed.ncbi.nlm.nih.gov/35417939>) DOI: 10.3324/haematol.2021.280352
(<https://doi.org/10.3324/haematol.2021.280352>) WoS: WOS:000870533100015
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000870533100015>)

